EP3613432A1 - Procédés de traitement de la polypose nasale par administration d'un antagoniste il-4r - Google Patents
Procédés de traitement de la polypose nasale par administration d'un antagoniste il-4r Download PDFInfo
- Publication number
- EP3613432A1 EP3613432A1 EP19187112.8A EP19187112A EP3613432A1 EP 3613432 A1 EP3613432 A1 EP 3613432A1 EP 19187112 A EP19187112 A EP 19187112A EP 3613432 A1 EP3613432 A1 EP 3613432A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- nasal
- score
- pharmaceutical composition
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 118
- 208000015768 polyposis Diseases 0.000 title claims abstract description 69
- 239000005557 antagonist Substances 0.000 title abstract description 142
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims abstract description 206
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims abstract description 206
- 239000000427 antigen Substances 0.000 claims abstract description 170
- 108091007433 antigens Proteins 0.000 claims abstract description 170
- 102000036639 antigens Human genes 0.000 claims abstract description 170
- 239000012634 fragment Substances 0.000 claims abstract description 153
- 238000011282 treatment Methods 0.000 claims description 149
- 208000024891 symptom Diseases 0.000 claims description 100
- 208000006673 asthma Diseases 0.000 claims description 87
- 208000000592 Nasal Polyps Diseases 0.000 claims description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims description 75
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 59
- 210000003979 eosinophil Anatomy 0.000 claims description 57
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 52
- 238000013134 sino-nasal outcome test Methods 0.000 claims description 49
- 201000009890 sinusitis Diseases 0.000 claims description 48
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 230000006872 improvement Effects 0.000 claims description 32
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims description 26
- 108010082169 Chemokine CCL17 Proteins 0.000 claims description 26
- 229940125369 inhaled corticosteroids Drugs 0.000 claims description 25
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 19
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 19
- 238000001356 surgical procedure Methods 0.000 claims description 19
- 206010027590 Middle insomnia Diseases 0.000 claims description 17
- 206010036790 Productive cough Diseases 0.000 claims description 16
- 230000002146 bilateral effect Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 210000003802 sputum Anatomy 0.000 claims description 16
- 208000024794 sputum Diseases 0.000 claims description 16
- 238000005259 measurement Methods 0.000 claims description 15
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 14
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 14
- 108010083698 Chemokine CCL26 Proteins 0.000 claims description 14
- 206010020751 Hypersensitivity Diseases 0.000 claims description 14
- 208000026935 allergic disease Diseases 0.000 claims description 14
- 229950003468 dupilumab Drugs 0.000 claims description 14
- 230000009610 hypersensitivity Effects 0.000 claims description 12
- 210000004086 maxillary sinus Anatomy 0.000 claims description 12
- 230000003434 inspiratory effect Effects 0.000 claims description 11
- 230000000007 visual effect Effects 0.000 claims description 11
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 9
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 claims description 9
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 claims description 9
- 102100037765 Periostin Human genes 0.000 claims description 8
- 101710199268 Periostin Proteins 0.000 claims description 8
- 238000013095 identification testing Methods 0.000 claims description 8
- 238000011269 treatment regimen Methods 0.000 claims description 4
- 229940090047 auto-injector Drugs 0.000 claims description 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 18
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 239000000902 placebo Substances 0.000 description 80
- 229940068196 placebo Drugs 0.000 description 80
- 239000003814 drug Substances 0.000 description 41
- 230000008859 change Effects 0.000 description 39
- 238000012216 screening Methods 0.000 description 37
- 239000003246 corticosteroid Substances 0.000 description 32
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 31
- 230000004044 response Effects 0.000 description 31
- 208000037874 Asthma exacerbation Diseases 0.000 description 28
- 238000002560 therapeutic procedure Methods 0.000 description 28
- 230000002829 reductive effect Effects 0.000 description 25
- 229940124597 therapeutic agent Drugs 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 24
- 210000004602 germ cell Anatomy 0.000 description 24
- 230000009467 reduction Effects 0.000 description 23
- 206010039101 Rhinorrhoea Diseases 0.000 description 22
- 239000000090 biomarker Substances 0.000 description 22
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 21
- 238000002648 combination therapy Methods 0.000 description 20
- 208000036071 Rhinorrhea Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 19
- 208000037062 Polyps Diseases 0.000 description 18
- 230000009885 systemic effect Effects 0.000 description 18
- 230000001684 chronic effect Effects 0.000 description 17
- 238000002591 computed tomography Methods 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 229940071648 metered dose inhaler Drugs 0.000 description 16
- 206010009137 Chronic sinusitis Diseases 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 15
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229960002714 fluticasone Drugs 0.000 description 15
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 15
- 229940114006 fluticasone / salmeterol Drugs 0.000 description 15
- 229960002052 salbutamol Drugs 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 229940112141 dry powder inhaler Drugs 0.000 description 14
- 229960002848 formoterol Drugs 0.000 description 14
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 13
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 230000002085 persistent effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 11
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 11
- 230000002378 acidificating effect Effects 0.000 description 11
- 229950008204 levosalbutamol Drugs 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 230000008786 sensory perception of smell Effects 0.000 description 11
- 150000003431 steroids Chemical class 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000003442 weekly effect Effects 0.000 description 11
- 206010001076 Acute sinusitis Diseases 0.000 description 10
- 206010016059 Facial pain Diseases 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 208000027744 congestion Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229960002744 mometasone furoate Drugs 0.000 description 10
- 210000003928 nasal cavity Anatomy 0.000 description 10
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 9
- 230000002411 adverse Effects 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 238000001839 endoscopy Methods 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 229960004017 salmeterol Drugs 0.000 description 9
- 206010002653 Anosmia Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 206010028735 Nasal congestion Diseases 0.000 description 8
- 206010028748 Nasal obstruction Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 239000007922 nasal spray Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 108010002616 Interleukin-5 Proteins 0.000 description 7
- 102000000743 Interleukin-5 Human genes 0.000 description 7
- 239000013566 allergen Substances 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229960004436 budesonide Drugs 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000002327 eosinophilic effect Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229940097496 nasal spray Drugs 0.000 description 7
- 210000001331 nose Anatomy 0.000 description 7
- 206010039083 rhinitis Diseases 0.000 description 7
- 210000001944 turbinate Anatomy 0.000 description 7
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 6
- 239000000850 decongestant Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000005713 exacerbation Effects 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 229960001664 mometasone Drugs 0.000 description 6
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 6
- -1 phosphoryl groups Chemical group 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010022095 Injection Site reaction Diseases 0.000 description 5
- 206010047924 Wheezing Diseases 0.000 description 5
- 229940090167 advair Drugs 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 239000003429 antifungal agent Substances 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000037916 non-allergic rhinitis Diseases 0.000 description 5
- 210000003695 paranasal sinus Anatomy 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 102000057955 Eosinophil Cationic Human genes 0.000 description 4
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 208000037656 Respiratory Sounds Diseases 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 4
- 229940125389 long-acting beta agonist Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004199 lung function Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 229940124624 oral corticosteroid Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010071380 Chronic hyperplastic eosinophilic sinusitis Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940080593 budesonide / formoterol Drugs 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229940103439 dulera Drugs 0.000 description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 229940003691 nasonex Drugs 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 229940035073 symbicort Drugs 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 208000027502 Ankle fracture Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010040744 Sinus headache Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229940085861 flovent Drugs 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 2
- 229960002329 methacholine Drugs 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013125 spirometry Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010071399 Chronic eosinophilic rhinosinusitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 238000012327 Endoscopic diagnosis Methods 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022056 Injection site dermatitis Diseases 0.000 description 1
- 206010022061 Injection site erythema Diseases 0.000 description 1
- 206010022066 Injection site haematoma Diseases 0.000 description 1
- 206010057880 Injection site nodule Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010022093 Injection site pruritus Diseases 0.000 description 1
- 206010022094 Injection site rash Diseases 0.000 description 1
- 206010053425 Injection site swelling Diseases 0.000 description 1
- 206010022107 Injection site urticaria Diseases 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 208000003892 Kartagener syndrome Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000029803 Young syndrome Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000013129 endoscopic sinus surgery Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940015979 epipen Drugs 0.000 description 1
- 210000001180 ethmoid sinus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001214 frontal sinus Anatomy 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940062714 humalog mix Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007436 olfactory function Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000003718 sphenoid sinus Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to the field of therapeutic treatments of inflammatory conditions. More specifically, the invention relates to the administration of interleukin-4 receptor (IL-4R) antagonists to treat nasal polyposis.
- IL-4R interleukin-4 receptor
- NP Nasal polyposis
- Th-2 T helper cell-2
- Eosinophils and their products are thought to be a hallmark of nasal polyp-associated inflammation as elevated levels of interleukin-5 (IL-5; promotes eosinophil survival and differentiation), eosinophil cationic protein (ECP), and eotaxin (eosinophil chemoattractant), factors that attract and activate eosinophils, are typically found in nasal polyps.
- IL-5 interleukin-5
- ECP eosinophil cationic protein
- eotaxin eosinophil chemoattractant
- Eosinophils are the predominant inflammatory cell found in the sinuses and nasal polyps, and nasal polyps are also associated with elevated levels of IgE.
- NP is characterized by long-term symptoms of nasal obstruction and congestion, reduction in or loss of sense of smell, anterior and posterior rhinorrhea, and facial pain.
- Current treatment options range from local or systemic corticosteroids to functional endoscopic sinus surgery.
- the invention provides a method for treating nasal polyposis, where the method includes administering to a subject in need thereof a pharmaceutical composition containing an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.
- IL-4R interleukin-4 receptor
- the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-4R ⁇ , such as an antibody or antigen binding fragment that comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2.
- the antibody or antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8.
- the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
- the IL-4R antagonist is dupilumab or an antigen-binding fragment thereof.
- Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and 7,608,693 .
- a subject suitable for treatment with an IL-4R antagonist may have one or more of sinusitis, rhinitis, asthma, aspirin hypersensitivity, non-steroidal anti-inflammatory drug (NSAID) hypersensitivity, or have previously undergone surgery to treat nasal polyposis.
- the subject has chronic sinusitis or chronic rhinosinusitis.
- the subject may have nasal polyposis with severe symptoms of sinusitis.
- the IL-4R antagonist is administered at a dose of 0.1 mg to 600 mg (e.g., 100 mg to 400 mg, such as 150 mg, 200 mg, 250 mg, 300 mg or 350 mg).
- the pharmaceutical composition is administered to the subject systemically or locally.
- the pharmaceutical composition may be administered subcutaneously, intravenously, or intranasally.
- the pharmaceutical composition is administered to the subject subcutaneously at a dose of 300 mg.
- one or more additional therapeutic agents are administered to the subject before, after or concurrent with the pharmaceutical composition comprising the IL-4R antagonist, such as the IL-4R antibody or antigen-binding fragment thereof.
- the one or more additional agents such as a second therapeutic agent can be a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, an NSAID (non-steroidal anti-inflammatory drug), an antibiotic, an anti-fungal agent, an intranasal corticosteroid, an inhaled corticosteroid, a systemic corticosteroid, a long-acting beta 2 agonist, a decongestant, or any combination thereof.
- the second therapeutic agent is an inhaled corticosteroid, such as fluticasone or budesonide, or an intranasal corticosteroid, such as mometasone furoate nasal spray (MFNS).
- the second therapeutic agent further includes a long-acting beta 2 agonist, such as salmeterol or formoterol.
- administration of the IL-4R antagonist is followed by an improvement in one or more symptoms of nasal polyposis.
- the administration of the antagonist can be followed by an improvement in one or more nasal polyposis-associated parameters, such as an improvement in a 22-item Sinonasal Outcome Test (SNOT-22) score; a nasal symptom score; number of nocturnal awakenings; a Visual Analog Score (VAS), such as for rhinosinusitis symptom severity; a five-item Asthma Control Questionnaire (ACQ5) score; nasal peak inspiratory flow (NPIF); the University of Pennsylvania Smell Identification Test (UPSIT); Lund-McKay Score; and three dimensional volumetric measurement of the maxillary sinus.
- SNOT-22 Sinonasal Outcome Test
- VAS Visual Analog Score
- ACQ5 five-item Asthma Control Questionnaire
- NPIF nasal peak inspiratory flow
- UPSIT University of Pennsylvania Smell Identification Test
- administration of the antibody or antigen binding fragment thereof is followed by one or more of an increase in one or both of NPIF and UPSIT, and a decrease in one or more of SNOT-22 score, nasal symptom score, VAS, Lund-McKay Score and 3D-Volumetric Score.
- administration of the IL-4R antagonist is followed by a decrease in nasal polyp score in the patient.
- the invention provides a method for treating nasal polyposis, by sequentially administering to a subject in need thereof a single initial dose of an interleukin-4 receptor (IL-4R) antagonist, such as an IL-4R antibody or an antigen-binding fragment thereof, followed by one or more secondary doses of the IL-4R antagonist.
- IL-4R interleukin-4 receptor
- each secondary dose is administered 1 to 15 weeks after the immediately preceding dose.
- at least three secondary doses of the IL-4R antagonist are administered to the subject, and each secondary dose is administered days or weeks (e.g., 1 week or 2 weeks or more) after the immediately preceding dose.
- the initial dose and the one or more secondary doses each include 50 mg to 500 mg of the IL-4R antagonist, e.g., 100 mg to 400 mg of the IL-4R antagonist, e.g., 150 mg, 200 mg, 250 mg, 300 mg, or 350 mg of the IL-4R antagonist.
- the initial dose and the one or more secondary doses each contain the same amount of the IL-4R antagonist.
- the initial dose comprises a first amount of the IL-4R antagonist
- the one or more secondary doses each comprise a second amount of the IL-4R antagonist.
- the first amount of the IL-4R antagonist can be 1.5x, 2x, 2.5x, 3x, 3.5x, 4x or 5x or more than the second amount of IL-4R antagonist.
- the subject e.g., a patient
- the subject has chronic sinusitis or chronic rhinosinusitis.
- the subject may have nasal polyposis with severe symptoms of sinusitis.
- the initial dose and the secondary doses of the IL-4R antagonist can be administered by the same or different routes of administration.
- the initial dose and the secondary doses can be administered subcutaneously, intravenously, or intranasally.
- administration of the initial dose and the one or more secondary doses is followed by an improvement in one or more nasal polyposis associated parameters, such as an improvement in a 22-item Sinonasal Outcome Test (SNOT-22) score; a nasal symptom score; number of nocturnal awakenings; a Visual Analog Score (VAS), such as for rhinosinusitis symptom severity; a five-item Asthma Control Questionnaire (ACQ5) score; nasal peak inspiratory flow (NPIF); the University of Pennsylvania Smell Identification Test (UPSIT); Lund-McKay Score; and three dimensional volumetric measurement of the maxillary sinus.
- SNOT-22 Sinonasal Outcome Test
- VAS Visual Analog Score
- ACQ5 five-item Asthma Control Questionnaire
- NPIF nasal peak inspiratory flow
- UPSIT University of Pennsylvania Smell Identification Test
- Lund-McKay Score and three dimensional volumetric measurement of the maxillary sinus.
- administration of the antibody or antigen binding fragment thereof is followed by one or more of an increase in one or both of NPIF and UPSIT, and a decrease in one or more of SNOT-22 score, nasal symptom score, VAS, Lund-McKay Score and 3D-Volumetric Score.
- administration of the IL-4R antagonist is followed by a decrease in nasal polyp score in the patient.
- one or more additional therapeutic agents are administered to the subject before, after or concurrent with the pharmaceutical composition comprising the IL-4R antagonist, such as the IL-4R antibody or antigen-binding fragment thereof.
- the one or more additional agents such as a second therapeutic agent can be a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, an NSAID, an antibiotic, an anti-fungal agent, an intranasal corticosteroid, an inhaled corticosteroid, a systemic corticosteroid, a long-acting beta 2 agonist, a decongestant, or any combination thereof.
- the second therapeutic agent is an inhaled corticosteroid, such as fluticasone or budesonide, or an intranasal corticosteroid, such as mometasone furoate nasal spray (MFNS).
- the second therapeutic agent further includes a long-acting beta 2 agonist, such as salmeterol or formoterol.
- the invention provides a method for treating nasal polyposis, by selecting a patient with a minimum bilateral nasal polyp score of 5, or at least two or more of the chronic symptoms of sinusitis selected from the group consisting of: nasal blockade/obstruction/congestion, anterior or posterior nasal drip, facial pain or pressure, and reduction or loss of smell; and administering to the selected patient a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), such that the patient's nasal polyp score is reduced or the two or more chronic symptoms of sinusitis are improved.
- an interleukin-4 receptor (IL-4R) antagonist such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R)
- the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-4R ⁇ , such as an antibody or antigen binding fragment that comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2.
- the antibody or antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8.
- the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
- the IL-4R antagonist is dupilumab or an antigen-binding fragment thereof.
- Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and 7,608,693 .
- the invention provides a method for treating nasal polyposis, by selecting a patient with a minimum bilateral nasal polyp score of 5, or at least two or more of the chronic symptoms of sinusitis selected from the group consisting of: nasal blockade/obstruction/congestion, anterior or posterior nasal drip, facial pain or pressure, and reduction or loss of smell; and sequentially administering to the patient a single initial dose of a pharmaceutical composition an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), followed by one or more secondary doses of the antibody or antigen binding fragment thereof, such that the patient's nasal polyp score is reduced or the two or more chronic symptoms of sinusitis are improved.
- IL-4R interleukin-4 receptor
- the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-4R ⁇ , such as an antibody or antigen binding fragment that comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2.
- the antibody or antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8.
- the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
- the IL-4R antagonist is dupilumab or an antigen-binding fragment thereof.
- Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and 7,608,693 .
- the invention provides a method for treating nasal polyposis, by determining in a subject the expression level of one or more genes selected from the group consisting of thymus and activation-regulated chemokine (TARC), eotaxin-3, periostin, carcinoembryonic antigen (CEA), and YKL-40; selecting the subject as a candidate for treatment with an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), if the subject has an elevated expression level of the one or more genes; and administering to the selected subject a pharmaceutical composition comprising an antibody or antigen binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), such that the level of the one or more genes is reduced.
- TARC thymus and activation-regulated chemokine
- eotaxin-3 eotaxin-3
- periostin periostin
- CEA carcinoembryonic anti
- the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-4R ⁇ , such as an antibody or antigen binding fragment that comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2.
- the antibody or antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8.
- the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
- the IL-4R antagonist is dupilumab or an antigen-binding fragment thereof.
- Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and 7,608,693 .
- the invention provides a method for treating nasal polyposis, by determining in a subject the expression level of one or more genes selected from the group consisting of thymus and activation-regulated chemokine (TARC), eotaxin-3, periostin, carcinoembryonic antigen (CEA), and YKL-40; selecting the subject as a candidate for treatment with an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), if the subject has an elevated expression level of the one or more genes; and sequentially administering to the selected subject a single initial dose of a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), followed by one or more secondary doses of the antibody or antigen binding fragment thereof, such that the level of the one or more genes is reduced.
- TARC thymus and
- the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-4R ⁇ , such as an antibody or antigen binding fragment that comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2.
- the antibody or antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8.
- the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
- the IL-4R antagonist is dupilumab or an antigen-binding fragment thereof.
- Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and 7,608,693 .
- the invention provides a method for treating nasal polyposis, by determining in a subject the level of blood eosinophils or sputum eosinophils; selecting the subject as a candidate for treatment with an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), if the subject has an elevated level of blood eosinophils or sputum eosinophils; and administering to the selected subject a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), such that the level of blood eosinophils or sputum eosinophils is reduced.
- an interleukin-4 receptor (IL-4R) antagonist such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R)
- the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-4R ⁇ , such as an antibody or antigen binding fragment that comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2.
- the antibody or antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8.
- the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
- the IL-4R antagonist is dupilumab or an antigen-binding fragment thereof.
- Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and 7,608,693 .
- the invention provides a method for treating nasal polyposis, by determining in a subject the level of blood eosinophils or sputum eosinophils; selecting the subject as a candidate for treatment with an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), if the subject has an elevated level of blood eosinophils or sputum eosinophils; and sequentially administering to the selected subject a single initial dose of a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), followed by one or more secondary doses of the antibody or antigen binding fragment thereof, such that the level of blood eosinophils or sputum eosinophils is reduced.
- an interleukin-4 receptor (IL-4R) antagonist such as antibody or
- the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-4R ⁇ , such as an antibody or antigen binding fragment that comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2.
- the antibody or antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8.
- the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
- the IL-4R antagonist is dupilumab or an antigen-binding fragment thereof.
- Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and 7,608,693 .
- FIG. 1 shows the schematic representation of an example of background therapy withdrawal time period in the treatment of an asthma patient.
- nasal polyposis As used herein, a "nasal polyp" is an overgrowth of tissue in one or more of the nasal cavities. The condition of nasal polyps is called “nasal polyposis.” About 80% of nasal polyps are highly edematous and filled with eosinophils. Nasal polyps can also present as fibrous, glandular or cystic.
- Nasal polyposis is a clinical condition characterized by the presence of multiple polyps in the upper nasal cavity, originating from the ostiomeatal complex.
- NP is a T helper cell-2 (Th-2) driven inflammatory process affecting the mucosa of the nose and paranasal sinuses.
- Eosinophils and their products are thought to be a hallmark of nasal polyp-associated inflammation as elevated levels of interleukin-5 (IL-5; promotes eosinophil survival and differentiation), eosinophil cationic protein (ECP), and eotaxin (eosinophil chemoattractant), factors that attract and activate eosinophils, are typically found in nasal polyps.
- Eosinophils are the predominant inflammatory cell found in the sinuses and nasal polyps, and nasal polyps are also associated with elevated levels of IgE.
- NP is characterized by long-term symptoms of nasal obstruction and congestion, reduction in or loss of sense of smell, anterior and posterior rhinorrhea, and facial pain.
- the presence or absence of nasal polyps can be confirmed for example by performing endoscopy, and the presence and extent of sinus and polyp involvement can be confirmed by methods such as coronal computed tomography (CT) scans.
- CT coronal computed tomography
- An IL-4R antagonist can be used to treat nasal polyposis associated with a variety of conditions.
- nasal polyposis is associated with sinusitis, rhinitis (e.g., allergic and non-allergic rhinitis), asthma (e.g., moderate-to-severe asthma), NSAID sensitivity (e.g., aspirin sensitivity), and infection, such as bacterial and fungal infection.
- Bacterial infections include, for example, staphylococcus infections.
- a subject with nasal polyposis can have a chronic infection, such as a chronic bacterial infection, e.g., a chronic staphylococcus aureus infection.
- the subject has recurring nasal polyposis, such as may be associated with recurring sinusitis.
- the subject as cystic fibrosis or NARES (Non-Allergic Rhinitis with Eosinophilia Syndrome).
- NARES Non-Allergic Rhinitis with Eosinophilia Syndrome
- the subject has a relapse of nasal polyposis after receiving surgery to treat the polyps.
- Risk factors for nasal polyposis include genetic susceptibility, anatomic abnormality, mucociliary impairment, infection, and local immunologic imbalance.
- An IL-4R antagonist can also be used to treat nasal polyposis in patients who have never previously received a treatment or surgery for NP.
- An IL-4R antagonist can also be used to treat nasal polyposis in patients who have previously undergone surgery, such as a nasal surgery, such as for treatment of nasal polyps.
- an IL-4R antagonist is administered to a subject whose nasal polyposis has relapsed after the subject received prior treatment for the polyps, such as a prior nasal surgery.
- nasal polyposis refers to any inflammatory condition characterized by inflammation of the paranasal sinuses, including inflammation of the maxillary, frontal, ethmoid and/or sphenoid paranasal sinuses.
- An IL-4R antagonist is suitable for treatment of nasal polyposis is associated with acute sinusitis, subacute sinusitis, chronic sinusitis and recurrent sinusitis.
- Acute sinusitis is characterized by a sudden onset of cold-like symptoms such as runny, stuffy nose and facial pain that does not go away after 10 to 14 days.
- Acute sinusitis typically lasts less than four weeks. Subacute sinusitis lasts four to eight weeks.
- Chronic sinusitis lasts eight weeks or longer, and recurrent sinusitis is characterized by sinusitis episodes that occur three or more times in one year. More than 80% of patients with chronic sinusitis with nasal polyps have eosinophilic upper airway inflammation.
- chronic hyperplastic eosinophilic sinusitis which is characterized by marked inflammation of the sinuses, increased eosinophils and mixed mononuclear cells, and a relative paucity of neutrophils.
- Some of these patients have one or more of associated nasal polyps, asthma, and aspirin or NSAID sensitivity.
- an IL-4R antagonist can be used to treat nasal polyposis in a subject who has chronic hyperplastic eosinophilic sinusitis.
- rhinitis refers to an allergic response, such as to a common allergen ("allergic rhinitis,” e.g., perennial allergic rhinitis) or to an environmental irritant ("non-allergic rhinitis”). Symptoms of allergic rhinitis include sneezing; stuffy or runny nose; sinus pressure, and pain or throbbing in the cheeks or nose; and itching in the nose, throat, eyes and ears.
- Non-allergic rhinitis Symptoms of non-allergic rhinitis include constriction or inflammation in the nasal passages which leads to many of the same symptoms of allergic rhinitis.
- Non-allergic rhinitis can be caused, for example, by strong chemical or smoky environments, or by long-term use of certain medications or dependency on nasal sprays.
- Rhinosinusitis refers to a condition that has symptoms of both rhinitis and sinusitis.
- Rhinosinusitis includes acute rhinosinusitis and chronic rhinosinusitis.
- Acute rhinosinusitis can be caused by an infection, such as a bacterial, viral or fungal infection, or by a chemical irritation.
- Cigarette-smoke-induced acute rhinosinusitis and chlorine fume-induced chronic rhinosinusitis are examples of acute rhinosinusitis.
- NP is most commonly associated with chronic rhinosinusitis (CRS), which is characterized by mucosal inflammation of the nasal cavity and paranasal sinuses with symptoms lasting more than 8 weeks.
- Chronic eosinophilic rhinosinusitis with nasal polyps is a condition that lasts longer than 8 weeks.
- Chronic sinusitis (CS) and chronic rhinosinusitis (CRS) are conditions that last longer than eight weeks.
- the underlying causes of acute sinusitis and acute rhinosinusitis may lead to chronic sinusitis or chronic rhinosinusitis if the resulting inflammation persists for more than 8 weeks.
- Chronic rhinosinusitis includes for example, eosinophilic chronic hyperplastic rhinosinusitis.
- chronic sinusitis and chronic rhinosinusitis
- superantigen-induced eosinophilic chronic sinusitis e.g., sinusitis induced by exo- and endo-toxins produced by bacteria such as Staphylococcus aureus
- allergic fungal sinusitis e.g., sinusitis induced by fungi such as Aspergillus or Alternaria
- non-allergic fungal eosinophilic chronic sinusitis e.g., sinusitis induced by fungi such as Aspergillus or Alternaria
- aspirin-exacerbated eosinophilic chronic sinusitis e.g., superantigen-induced eosinophilic chronic sinusitis (e.g., sinusitis induced by exo- and endo-toxins produced by bacteria such as Staphylococcus aureus )
- allergic fungal sinusitis e.g., sinusitis induced by fungi such as Aspergillus or Alternaria
- An IL-4R antagonist can be used to treat nasal polyposis in subjects having any of the disorders described above.
- the present invention includes methods for improving one or more nasal polyp-associated parameters in a subject in need thereof, wherein the methods include administering a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist to the subject.
- IL-4R interleukin-4 receptor
- an IL-4R receptor antagonist can reduce endoscopic nasal polyp score in a patient.
- a nasal polyp score of 0 indicates the presence of no polyps.
- a nasal polyp score of 1 indicates the presence of small polyps in the middle meatus not reaching below the inferior border of the middle turbinate.
- a nasal polyp score of 3 indicates large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate.
- a nasal polyp score of 4 indicates large polyps causing complete obstruction of the inferior nasal cavity (see Table 15 below).
- treatment with an IL-4R antagonist can decrease nasal polyp score by about 1 to about 8 points.
- treatment with an IL-4R antagonist can decrease nasal polyp score by about 1 point or more, by about 2 points or more, or by about 3 points or more.
- treatment with an IL-4R antagonist can decrease nasal polyp score by about 1 point, or a fraction thereof; by 2 points, or a fraction thereof; by 3 points, or a fraction thereof; by 4 points, or a fraction thereof; by 5 points, or a fraction thereof; by 6 points, or a fraction thereof; by 7 points, or a fraction thereof; or by 8 points or a fraction thereof.
- a reduction in nasal polyp score may correlate with an improvement in one or more other nasal polyp-associated parameters. Such a correlation, however, is not necessarily observed in all cases.
- nasal polyp-associated parameters include: (a) 22-item SinoNasal Outcome Test (SNOT-22) score; (b) subject-assessed nasal congestion/obstruction, anterior rhinorrhea (runny nose), posterior rhinorrhea (post nasal drip) and loss of sense of smell; (c) number of nocturnal awakenings; (d) Visual Analog Score (VAS) to assess patient-rated rhinosinusitis symptom severity; (e) five-item Asthma Control Questionnaire (ACQ5) score, such as in patients with asthma; (f) Nasal Peak Inspiratory Flow (NPIF); (g) smell test (University of Pennsylvania Smell Identification Test (UPSIT)); (h) physiological parameters, such as measured by nasal endoscopy and CT scan; (i) Lund-Mackay Score; and (j) Three Dimensional volumetric measurement of the maxillary sinus.
- SNOT-22 22-item SinoNasal Outcome Test
- NPIF Nas
- 22-Item Sinonasal Outcome Test (SNOT-22) Score .
- administration of an IL-4R antagonist to a patient results in a decrease from baseline of 22-item Sinonasal Outcome Test (SNOT-22).
- the SNOT-22 is a questionnaire to assess the impact of chronic rhinosinusitis (CRS) on quality of life.
- CRS chronic rhinosinusitis
- the questionnaire measures items related to sinonasal conditions and surgical treatments. The score ranges from 0 to 110, and higher scores imply greater impact of CRS on Health Related Quality of Life (HRQoL) ( Hopkins et al 2009, Clin. Otolaryngol. 34: 447-454 ).
- the present invention includes therapeutic methods that result in a decrease in SNOT-22 score from baseline of at least 1 point at week 4 to week 16 following administration of the IL-4R antagonist.
- administration of an IL-4R antagonist will result in a decrease in SNOT-22 score at week 4, week 6, week 8, week 12, or week 16 following initiation of treatment.
- administration of an IL-4R antagonist to a subject in need thereof causes a decrease in SNOT-22 score from baseline of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 points, or more at week 4, week 6, week 8 or week 12.
- Administration of an IL-4R antagonist can result, for example, in a decrease in average number of nighttime awakenings per night from baseline of at least about 0.10 times per night at week 4 to week 16 following initiation of treatment with a pharmaceutical composition comprising an anti-IL-4R antagonist.
- a decrease in frequency of nighttime awakenings per night from baseline of at least about 0.10 times per night can be detected at week 4, week 6, week 8, week 12, or week 16 following initiation of treatment.
- Administration of an IL-4R antagonist to a subject in need thereof can cause a decrease in average number of nighttime awakenings per night from baseline by about 0.10 times per night, 0.15 times per night, 0.20 times per night, 0.25 times per night, 0.30 times per night, 0.35 times per night, 0.40 times per night, 0.45 times per night, 0.50 times per night, 0.55 times per night, 0.60 times per night, 0.65 times per night, 0.70 times per night, 0.75 times per night, 0.80 times per night, 0.85 times per night, 0.90 times per night, 0.95 times per night, 1.0 time per night, 2.0 times per night, or more at week 4, week 8, week 12, or week 16, for example.
- VAS Visual Analog Score
- the VAS is a measure to assess patient-related rhinosinusitis symptom severity on a scale of 1 to 10. Mild symptoms are indicated by a score of 0 to 3, moderate symptoms are indicated by a VAS score of >3 to 7, and severe symptoms are indicated by a VAS score of >7 to 10.
- Administration of an IL-4R antagonist to a subject in need thereof causes a decrease in VAS score from baseline of about 0.5 point, 1 point, 1.5 points, 2 points, 2.5 points, 3 points, 3.5 points, 4 points, or more at week 4, week 6 or week 12.
- the decrease in VAS score can be detected as early as week 4, and as late as week 12 or later following administration of the IL-4R antagonist.
- ACQ 5-Item Asthma Control Questionnaire
- the present invention includes therapeutic methods which result in a decrease in ACQ5 score from baseline of at least 0.10 point at week 12 following initiation of treatment with a pharmaceutical composition comprising an anti-IL-4R antagonist.
- administration of an IL-4R antagonist to a subject in need thereof causes a decrease in ACQ score from baseline of about 0.10 points, 0.15 points, 0.20 points, 0.25 points, 0.30 points, 0.35 points, 0.40 points, 0.45 points, 0.50 points, 0.55 points, 0.60 points, 0.65 points, 0.70 points, 0.75 points, 0.80 points, 0.85 points, or more at week 4, week 6 or week 12.
- the decrease in ACQ score can be detected as early as week 4, and as late as week 12 or later following administration of the IL-4R antagonist.
- Nasal Peak Inspiratory Flow NPIF
- the Nasal Peak Inspiratory Flow NPIF represents a physiologic measure of air flow through both nasal cavities during forced inspiration and/or expiration expressed in liters per minute. Nasal inspiration correlates most with the subjective feeling of obstruction and is used to monitor nasal flow.
- Administration of an IL-4R antagonist to a subject in need thereof causes an increase in NPIF from baseline by about 0.10 liters per minute, 0.15 liters per minute, 0.20 liters per minute, 0.25 liters per minute, 0.30 liters per minute, 0.35 liters per minute, 0.40 liters per minute, 0.45 liters per minute, 0.50 liters per minute, 0.55 liters per minute, 0.60 liters per minute, 0.65 liters per minute, 0.70 liters per minute, 0.75 liters per minute, 0.80 liters per minute, 0.85 liters per minute, or more at week 4, week 6 or week 12.
- the increase in NPIF score can be detected as early as week 4, and as late as week 12 or later following administration of the IL-4R antagonist.
- UPSIT University of Pennsylvania Smell Identification Test
- the UPSIT is a method to quantitatively assess human olfactory function.
- the test consists of samples of odorants, and the subject has to describe the odor. The score is based on the number of correct answers. This test can distinguish patients with a normal sense of smell ("normosmia") from those with different levels of reduction (“mild, moderate and severe microsmia”) or loss ("anosmia”).
- Administration of an IL-4R antagonist to a subject in need thereof causes an increase in UPSIT score from baseline by about 0.5 points, 1 point, 1.5 points, 2 points, 2.5 points, 3 points, 3.5 points or more at week 4, week 6 or week 12.
- the increase in UPSIT score can be detected as early as week 4, and as late as week 12 or later following administration of the IL-4R antagonist.
- Efficacy of an IL-4R antagonist can be assayed by measuring the effect of physiological parameters, such as within the nasal cavities, such as by nasal endoscopy or computed tomography (CT) scan.
- CT computed tomography
- an IL-4R antagonist to a subject in need thereof causes a decrease in Lund-Mackay score from baseline by about 0.10 points, 0.15 points, 0.20 points, 0.25 points, 0.30 points, 0.35 points, 0.40 points, 0.45 points, 0.50 points, 0.55 points, 0.60 points, 0.65 points, 0.70 points, 0.75 points, 0.80 points, 0.85 points, or more at week 4, week 6 or week 12.
- the decrease in Lund-Mackay score can be detected as early as week 4, and as late as week 12 or later following administration of the IL-4R antagonist.
- Three-Dimensional volumetric measurement of maxillary sinus This value is used to calculate the volume of air (mL); the volume of mucosa (mL); the percent sinus occupied by disease; and the thickness of lateral wall in the maxillary sinus.
- Administration of an IL-4R antagonist to a subject in need thereof causes an increase in the Three-Dimensional volumetric measurement.
- QoL Questionnaires can be used to monitor efficacy of an IL-4R antagonist, including Short-Form-36 (SF-36) Questionnaire, the Euroqol-5D (EQ-5D), nasal polyp related resource use questionnaire, and the patient qualitative self-assessment.
- SF-36 Short-Form-36
- EQ-5D Euroqol-5D
- nasal polyp related resource use questionnaire nasal polyp related resource use questionnaire
- the SF-36 is a 36 item questionnaire that measures eight multi-item dimensions of health: physical functioning (10 items) social functioning (2 items) role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items).
- item scores are coded, summed, and transformed on a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).
- Two standardized summary scores can also be calculated from the SF-36; the physical component summary (PCS) and the mental health component summary (MCS).
- the EQ-5D is a standardized health-related quality of life questionnaire developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal and inter-disease comparisons.
- EQ-5D designed for self-completion by patients, consists of two parts, the EQ-5D descriptive system and the EQ VAS.
- the EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression; and each dimension has 3 levels: no problem, some problems, severe problems.
- the EQ Visual Analogue Scale (VAS) records the respondent's self-rated health on a vertical visual analogue scale.
- the EQ VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom.
- the nasal polyp related resource use questionnaire is a questionnaire of health care resource utilization for nasal polyposis, including specialist visits, emergency care visits, sick leaves, days off etc.
- Improvement of a nasal polyp-associated parameter can be expressed as a percentage. For example, a score can be improved by 30% or more, by 40% or more, by 50% or more, by 60% or more, by 70% or more, or by 80% or more.
- An “improvement in a nasal polyp-associated parameter” means an increase from baseline of one or more of NPIF, UPSIT, and/or a decrease from baseline of one or more of SNOT-22 score, subject-assessed nasal congestion/obstruction, anterior rhinorrhea (runny nose), posterior rhinorrhea (post nasal drip) and loss of sense of smell; number of nocturnal awakenings; VAS score; Lund-Mackay score; and 3D volumetric scores; and ACQ5 score in patients with asthma.
- the term "baseline,” with regard to a nasal polyp-associated parameter means the numerical value of the nasal polyp-associated parameter for a patient prior to or at the time of administration of a pharmaceutical composition of the present invention.
- a nasal polyp-associated parameter is quantified at baseline and at a time point after administration of the pharmaceutical composition of the present invention.
- a nasal polyp-associated parameter may be measured at day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 14, or at week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12, week 13, week 14, week 15, week 16, week 17, week 18, week 19, week 20, week 21, week 22, week 23, week 24, or longer, after the initial treatment with a pharmaceutical composition of the present invention.
- the parameter is measured daily (e.g., once or twice per day), weekly, biweekly, or monthly.
- the parameter is measured daily and the mean value determined over the course of a month is compared to baseline.
- the difference between the value of the parameter at a particular time point following initiation of treatment and the value of the parameter at baseline is used to establish whether there has been an "improvement" in the nasal associated parameter (e.g., an increase or decrease, as the case may be, depending on the specific parameter being measured).
- a subject in need thereof is administered a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist.
- an "IL-4R antagonist” is any agent that binds to or interacts with IL-4R and inhibits the normal biological signaling function of IL-4R when IL-4R is expressed on a cell in vitro or in vivo.
- Non-limiting examples of categories of IL-4R antagonists include small molecule IL-4R antagonists, peptide-based IL-4R antagonists (e.g., "peptibody” molecules), and antibodies or antigen-binding fragments of antibodies that specifically bind human IL-4R.
- human IL-4R (hIL-4R), as used herein, is intended to refer to the IL-4R ⁇ subunit, which is a component of the IL-4 receptors Type I and Type II, as well as the IL-13 receptor system.
- An IL-4R antagonist such as an anti-IL-4R ⁇ antibody or antigen-binding fragment thereof, blocks the function of both IL-4 and IL-13 signal transduction.
- antibody is intended to refer to immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM).
- Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or V H ) and a heavy chain constant region.
- the heavy chain constant region comprises three domains, C H 1, C H 2 and C H 3.
- Each light chain comprises a light chain variable region (abbreviated herein as LCVR or V L ) and a light chain constant region.
- the light chain constant region comprises one domain (C L 1).
- V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
- CDRs complementarity determining regions
- FR framework regions
- Each V H and V L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the FRs of the anti-Ang-2 antibody may be identical to the human germline sequences, or may be naturally or artificially modified.
- An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
- antibody also includes antigen-binding fragments of full antibody molecules.
- antigen-binding portion of an antibody, “antigen-binding fragment” of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex.
- Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains.
- DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized.
- the DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
- Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide.
- CDR complementarity determining region
- engineered molecules such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment," as used herein.
- SMIPs small modular immunopharmaceuticals
- an antigen-binding fragment of an antibody will typically comprise at least one variable domain.
- the variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences.
- the V H and V L domains may be situated relative to one another in any suitable arrangement.
- the variable region may be dimeric and contain V H -V H , V H -V L or V L -V L dimers.
- the antigen-binding fragment of an antibody may contain a monomeric V H or V L domain.
- an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain.
- variable and constant domains that may be found within an antigen-binding fragment of an antibody include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1 -C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3; (xiii) V L -C H 2-C H 3; and (xiv) V L -C
- variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region.
- a hinge region may consist of at least 2 ( e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule.
- an antigen-binding fragment of an antibody may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V H or V L domain ( e.g., by disulfide bond(s)).
- antigen-binding fragments may be monospecific or multispecific (e.g., bispecific).
- a multispecific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen.
- Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an anti-IL-4R antibody using routine techniques available in the art.
- the constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity.
- the isotype of an antibody may be selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity.
- human antibody is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
- the human antibodies featured in the invention may nonetheless include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo ), for example in the CDRs and in particular CDR3.
- the term "human antibody”, as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
- recombinant human antibody is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295 ) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences.
- Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences.
- such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the V H and V L regions of the recombinant antibodies are sequences that, while derived from and related to human germline V H and V L sequences, may not naturally exist within the human antibody germline repertoire in vivo.
- an immunoglobulin molecule comprises a stable four chain construct of approximately 150-160 kDa in which the dimers are held together by an interchain heavy chain disulfide bond.
- the dimers are not linked via inter-chain disulfide bonds and a molecule of about 75-80 kDa is formed composed of a covalently coupled light and heavy chain (half-antibody).
- the frequency of appearance of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody.
- a single amino acid substitution in the hinge region of the human IgG4 hinge can significantly reduce the appearance of the second form ( Angal et al. (1993) Molecular Immunology 30:105 ) to levels typically observed using a human IgG1 hinge.
- the instant invention encompasses antibodies having one or more mutations in the hinge, C H 2 or C H 3 region which may be desirable, for example, in production, to improve the yield of the desired antibody form.
- an “isolated antibody,” as used herein, means an antibody that has been identified and separated and/or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced, is an “isolated antibody.”
- An isolated antibody also includes an antibody in situ within a recombinant cell. Isolated antibodies are antibodies that have been subjected to at least one purification or isolation step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and/or chemicals.
- the term "specifically binds,” or the like, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions.
- Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.
- an antibody that "specifically binds" IL-4R includes antibodies that bind IL-4R or portion thereof with a K D of less than about 1000 nM, less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM or less than about 0.5 nM, as measured in a surface plasmon resonance assay.
- An isolated antibody that specifically binds human IL-4R may, however, have cross-reactivity to other antigens, such as IL-4R molecules from other (non
- the anti-IL-4R antibodies useful for the methods featured herein may include one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases.
- the present invention includes methods involving the use of antibodies, and antigen-binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as "germline mutations").
- Germline mutations A person of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline mutations or combinations thereof.
- all of the framework and/or CDR residues within the V H and/or V L domains are mutated back to the residues found in the original germline sequence from which the antibody was derived.
- only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3.
- one or more of the framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different germline sequence (i.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived).
- the antibodies may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence.
- antibodies and antigen-binding fragments that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc.
- desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc.
- the use of antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present invention.
- the present invention also includes methods involving the use of anti-IL-4R antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions.
- the present invention includes the use of anti-IL-4R antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.
- surface plasmon resonance refers to an optical phenomenon that allows for the analysis of real-time interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcoreTM system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
- K D is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.
- epitope refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope.
- a single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects.
- Epitopes may be either conformational or linear.
- a conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain.
- a linear epitope is one produced by adjacent amino acid residues in a polypeptide chain.
- an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.
- the IL-4R antagonist is an anti-IL-4R ⁇ antibody, or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR), light chain variable region (LCVR), and/or complementarity determining regions (CDRs) comprising any of the amino acid sequences of the anti-IL-4R antibodies as set forth in US Patent Nos. 7,608,693 and 7,605,237 .
- HCVR heavy chain variable region
- LCVR light chain variable region
- CDRs complementarity determining regions
- the anti-IL-4R ⁇ antibody or antigen-binding fragment thereof that can be used in the context of the methods of the present invention comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.
- the anti-IL-4R ⁇ antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3; the HCDR2 comprises the amino acid sequence of SEQ ID NO:4; the HCDR3 comprises the amino acid sequence of SEQ ID NO:5; the LCDR1 comprises the amino acid sequence of SEQ ID NO:6; the LCDR2 comprises the amino acid sequence of SEQ ID NO:7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.
- the anti-IL-4R antibody or antigen-binding fragment thereof comprises an HCVR comprising SEQ ID NO:1 and an LCVR comprising SEQ ID NO:2.
- the methods of the present invention comprise the use of the anti-IL-4R ⁇ antibody referred to and known in the art as dupilumab, or a bioequivalent thereof.
- bioequivalent refers to a molecule having similar bioavailability (rate and extent of availability) after administration at the same molar dose and under similar conditions (e.g., same route of administration), such that the effect, with respect to both efficacy and safety, can be expected to be essentially same as the comparator molecule.
- Two pharmaceutical compositions comprising an IL-4R antagonist are bioequivalent if they are pharmaceutically equivalent, meaning they contain the same amount of active ingredient (e.g., IL-4R antagonist), in the same dosage form, for the same route of administration and meeting the same or comparable standards.
- Bioequivalence can be determined, for example, by an in vivo study comparing a pharmacokinetic parameter for the two compositions. Parameters commonly used in bioequivalence studies include peak plasma concentration (C max ) and area under the plasma drug concentration time curve (AUC).
- the anti-IL-4R ⁇ antibodies used in the context of the methods of the present invention may have pH-dependent binding characteristics.
- an anti-IL-4R ⁇ antibody for use in the methods of the present invention may exhibit reduced binding to IL-4R ⁇ at acidic pH as compared to neutral pH.
- an anti-IL-4R ⁇ antibody of the invention may exhibit enhanced binding to its antigen at acidic pH as compared to neutral pH.
- the expression "acidic pH” includes pH values less than about 6.2, e.g., about 6.0, 5.95, 5,9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less.
- neutral pH means a pH of about 7.0 to about 7.4.
- the expression “neutral pH” includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
- "reduced binding to IL-4R ⁇ at acidic pH as compared to neutral pH” is expressed in terms of a ratio of the K D value of the antibody binding to IL-4R ⁇ at acidic pH to the K D value of the antibody binding to IL-4R ⁇ at neutral pH (or vice versa).
- an antibody or antigen-binding fragment thereof may be regarded as exhibiting "reduced binding to IL-4R ⁇ at acidic pH as compared to neutral pH” for purposes of the present invention if the antibody or antigen-binding fragment thereof exhibits an acidic/neutral K D ratio of about 3.0 or greater.
- the acidic/neutral K D ratio for an antibody or antigen-binding fragment of the present invention can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0. 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0 or greater.
- Antibodies with pH-dependent binding characteristics may be obtained, e.g., by screening a population of antibodies for reduced (or enhanced) binding to a particular antigen at acidic pH as compared to neutral pH. Additionally, modifications of the antigen-binding domain at the amino acid level may yield antibodies with pH-dependent characteristics. For example, by substituting one or more amino acids of an antigen-binding domain (e.g., within a CDR) with a histidine residue, an antibody with reduced antigen-binding at acidic pH relative to neutral pH may be obtained.
- the expression "acidic pH” means a pH of 6.0 or less.
- the present invention includes methods which include administering an IL-4R antagonist to a patient, where the IL-4R antagonist is contained within a pharmaceutical composition.
- the pharmaceutical compositions featured in the invention are formulated with suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA .
- formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTINTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311 .
- the dose of antibody administered to a patient may vary depending upon the age and the size of the patient, symptoms, conditions, route of administration, and the like.
- the preferred dose is typically calculated according to body weight or body surface area.
- the frequency and the duration of the treatment can be adjusted.
- Effective dosages and schedules for administering pharmaceutical compositions comprising anti-IL-4R antibodies may be determined empirically; for example, patient progress can be monitored by periodic assessment, and the dose adjusted accordingly.
- interspecies scaling of dosages can be performed using well-known methods in the art (e.g., Mordenti et al., 1991, Pharmaceut. Res. 8:1351 ).
- IL-4R antagonists include encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432 ).
- Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
- composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
- infusion or bolus injection by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
- epithelial or mucocutaneous linings e.g., oral mucosa, rectal and intestinal mucosa, etc.
- a pharmaceutical composition can be delivered subcutaneously or intravenously with a standard needle and syringe.
- a pen delivery device readily has applications in delivering a pharmaceutical composition.
- Such a pen delivery device including an autoinjection pen delivery device, can be reusable or disposable.
- a reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused.
- a disposable pen delivery device there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.
- Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition. Examples include, but are not limited to AUTOPENTM (Owen Mumford, Inc., Woodstock, UK), DISETRONICTM pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25TM pen, HUMALOGTM pen, HUMALIN 70/30TM pen (Eli Lilly and Co., Indianapolis, IN), NOVOPENTM I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIORTM (Novo Nordisk, Copenhagen, Denmark), BDTM pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPENTM, OPTIPEN PROTM, OPTIPEN STARLETTM, and OPTICLIKTM (sanofi-aventis, Frankfurt, Germany), to name only a few.
- Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition include, but are not limited to the SOLOSTARTM pen (sanofi-aventis), the FLEXPENTM (Novo Nordisk), and the KWIKPENTM (Eli Lilly), the SURECLICKTM Autoinjector (Amgen, Thousand Oaks, CA), the PENLETTM (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.), and the HUMIRATM Pen (Abbott Labs, Abbott Park IL), to name only a few.
- SOLOSTARTM pen sinofi-aventis
- the FLEXPENTM Novo Nordisk
- KWIKPENTM Eli Lilly
- SURECLICKTM Autoinjector Amgen, Thousand Oaks, CA
- the PENLETTM Heaselmeier, Stuttgart, Germany
- EPIPEN Dey, L.P.
- HUMIRATM Pen Abbott Labs, Abbott Park IL
- the pharmaceutical compositions containing IL-4R antagonists may be administered using, e.g., a microcatheter (e.g., an endoscope and microcatheter), an aerosolizer, a powder dispenser, a nebulizer or an inhaler.
- the pharmaceutical composition can be delivered in a controlled release system.
- a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201 ).
- polymeric materials can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida .
- a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 ).
- Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527 -1533 .
- the injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections.
- aqueous medium for injections there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc.
- an alcohol e.g., ethanol
- a polyalcohol e.g., propylene glycol, polyethylene glycol
- a nonionic surfactant e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil
- oily medium there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
- a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
- the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients.
- dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
- the amount of IL-4R antagonist (e.g., anti-IL-4R antibody, or antigen binding fragment thereof) administered to a subject according to the methods featured herein is generally a therapeutically effective amount.
- therapeutically effective amount means a dose of IL-4R antagonist that results in a detectable improvement in one or more symptoms associated with nasal polyps, or a dose of IL-4R antagonist that inhibits, prevents, lessens, or delays the progression of nasal polyps or a condition associated with nasal polyps.
- a therapeutically effective amount can be from about 0.05 mg to about 600 mg, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg,
- the amount of IL-4R antagonist contained within the individual doses may be expressed in terms of milligrams of antibody per kilogram of patient body weight (i.e., mg/kg).
- the IL-4R antagonist may be administered to a patient at a dose of about 0.0001 to about 10 mg/kg of patient body weight.
- the methods include administering to the subject one or more additional therapeutic agents in combination with the IL-4R antagonist.
- the expression "in combination with” means that the additional therapeutic agents are administered before, after, or concurrent with the pharmaceutical composition comprising the IL-4R antagonist.
- the additional therapeutic agent may be administered about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, about 15 minutes or about 10 minutes prior to the administration of the pharmaceutical composition comprising the IL-4R antagonist.
- the additional therapeutic agent When administered “after" the pharmaceutical composition comprising the IL-4R antagonist, the additional therapeutic agent may be administered about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours or about 72 hours after the administration of the pharmaceutical composition comprising the IL-4R antagonist.
- Administration "concurrent" with the pharmaceutical composition comprising the IL-4R antagonist means that the additional therapeutic agent is administered to the subject in a separate dosage form within less than 5 minutes (before, after, or at the same time) of administration of the pharmaceutical composition comprising the IL-4R antagonist, or administered to the subject as a single combined dosage formulation comprising both the additional therapeutic agent and the IL-4R antagonist.
- the additional therapeutic agent may be, e.g., another IL-4R antagonist, an IL-1 antagonist (including, e.g., an IL-1 antagonist as set forth in US Patent No. 6,927,044 ), an IL-6 antagonist, an IL-6R antagonist (including, e.g., an anti-IL-6R antibody as set forth in US Patent No.
- an IL-13 antagonist e.g., a TNF antagonist, an IL-8 antagonist, an IL-9 antagonist, an IL-17 antagonist, an IL-5 antagonist, an IgE antagonist, a CD48 antagonist, an antibiotic (e.g., doxycycline), an anti-fungal agent, a leukotriene, an antihistamine, an ⁇ -adrenergic decongestant, a mucolytic, an NSAID, a long-acting beta 2 agonist (e.g., salmeterol or formoterol), a short-acting beta 2 agonist, a steroid (e.g., an oral steroid), a corticosteroid, such as an intranasal corticosteroid (e.g., mometasone furoate (MFNS; e.g., Nasonex®)), or an inhaled corticosteroid (e.g., fluticasone or budesonide), an allergen immunotherapy
- the pharmaceutical composition comprising an IL-4R antagonist is administered in combination with a combination comprising a long-acting beta 2 agonist and an inhaled corticosteroid (e.g., fluticasone + salmeterol [e.g., Advair® (GlaxoSmithKline)]; or budesonide + formoterol [ e.g., Symbicort® (Astra Zeneca)]).
- a combination comprising a long-acting beta 2 agonist and an inhaled corticosteroid e.g., fluticasone + salmeterol [e.g., Advair® (GlaxoSmithKline)]; or budesonide + formoterol [ e.g., Symbicort® (Astra Zeneca)]
- a long-acting beta 2 agonist e.g., fluticasone + salmeterol [e.g., Advair® (GlaxoSmithKline)]
- the IL-4R antagonist is administered after a subject receives surgery to treat nasal polyposis.
- multiple doses of an IL-4R antagonist may be administered to a subject over a defined time course.
- the methods include, for example, sequentially administering to a subject multiple doses of an IL-4R antagonist.
- sequentially administering means that each dose of IL-4R antagonist is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval ( e.g., hours, days, weeks or months).
- the present invention includes methods which comprise sequentially administering to the patient a single initial dose of an IL-4R antagonist, followed by one or more secondary doses of the IL-4R antagonist, and optionally followed by one or more tertiary doses of the IL-4R antagonist.
- the terms “initial dose,” “secondary doses,” and “tertiary doses,” refer to the temporal sequence of administration of the IL-4R antagonist.
- the “initial dose” is the dose which is administered at the beginning of the treatment regimen (also referred to as the “baseline dose”);
- the “secondary doses” are the doses which are administered after the initial dose;
- the “tertiary doses” are the doses which are administered after the secondary doses.
- the initial, secondary, and tertiary doses may all contain the same amount of IL-4R antagonist, but will generally differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of IL-4R antagonist contained in the initial, secondary and/or tertiary doses will vary from one another ( e.g., adjusted up or down as appropriate) during the course of treatment.
- each secondary and/or tertiary dose is administered 1 to 14 (e.g., 1, 11 ⁇ 2, 2, 21 ⁇ 2, 3,31 ⁇ 2, 4, 41 ⁇ 2, 5, 51 ⁇ 2, 6, 61 ⁇ 2, 7, 71 ⁇ 2, 8, 81 ⁇ 2, 9, 91 ⁇ 2, 10, 101 ⁇ 2, 11, 111 ⁇ 2, 12, 121 ⁇ 2, 13, 131 ⁇ 2, 14, 141 ⁇ 2, or more) weeks after the immediately preceding dose.
- the phrase "the immediately preceding dose,” as used herein, means, in a sequence of multiple administrations, the dose of IL-4R antagonist which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.
- These methods may include administering to a patient any number of secondary and/or tertiary doses of an IL-4R antagonist.
- any number of secondary and/or tertiary doses of an IL-4R antagonist may include administering to a patient any number of secondary and/or tertiary doses of an IL-4R antagonist.
- only a single secondary dose is administered to the patient.
- two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient.
- only a single tertiary dose is administered to the patient.
- two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.
- each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1 to 2 weeks after the immediately preceding dose.
- each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2 to 4 weeks after the immediately preceding dose.
- the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient following clinical examination.
- the initial dose (e.g., a "loading dose”) is higher than either or both of the secondary and tertiary doses.
- the initial dose can be a loading dose, which is 1.5x, 2x, 2.5x, 3x or more greater than the secondary dose.
- a subject in need thereof means a human or non-human animal that exhibits one or more symptoms or indication of nasal polyposis, or who has been diagnosed with nasal polyposis, or chronic symptoms of sinusitis.
- a subject in need thereof has bilateral nasal polyps, and a nasal polyp score of at least 5 out of a maximum of 8 for both nostrils, with at least a score of 2 for each nostril.
- the polyps are in the middle meatus.
- the presence of nasal polyps is confirmed by endoscopy.
- the subject also has bilateral mucosal disease, which is confirmed by a method such as CT scan.
- bilateral mucosal disease is an infection of the mucous lining of the sinus cavities, e.g., the maxillary sinus cavities.
- nasal polyposis e.g., a nasal polyp score of at least 5 out of a maximum of 8 for both nostrils, with at least a score of 2 for each nostril
- ICS inhaled corticosteroids
- a subject in need thereof has anterior and/or posterior mucopurulent drainage, nasal obstruction, and a decreased sense of smell.
- a subject in need thereof has had symptoms of nasal polyposis for 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks or more.
- the subject has received a previous treatment, such as with an intranasal corticosteroid (e.g., MFNS), for at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks or longer, prior to receiving treatment with an IL-4R antagonist.
- the subject will continue to receive the INCS while receiving treatment with the IL-4R antagonist.
- the subject stops receiving the INCS before receiving treatment with the IL-4R antagonist, or the subject stops receiving treatment with the INCS if administration with the IL-4R antagonist is effective to treat the nasal polyposis.
- the subject tapers the dose of the INCS before stopping treatment completely.
- a subject in need thereof may further have been diagnosed with nasal polyposis on the basis of one or more of the following: (a) 22-item SinoNasal Outcome Test (SNOT-22) score; (b) subject-assessed nasal congestion/obstruction, anterior rhinorrhea, posterior rhinorrhea and loss of sense of smell; (c) number of nocturnal awakenings; (d) Visual Analog Score (VAS) to assess patient-rated rhinosinusitis symptom severity; (e) five-item Asthma Control Questionnaire (ACQ5) score in patients with asthma; (f) Nasal Peak Inspiratory Flow (NPIF); (g) smell test (University of Pennsylvania Smell Identification Test (UPSIT); (h) physiological parameters, such as measured by nasal endoscopy and CT scan; (i) Lund-Mackay Score; and (k) Three Dimensional volumetric measurement of the maxillary sinus.
- SNOT-22 22-item SinoNasal Outcome Test
- SNOT-22
- a "subject in need thereof” is a human patient with chronic symptoms of sinusitis, which are the presence of at least two of the following symptoms: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; and reduction or loss of smell.
- a "subject in need thereof” is a human patient with a SNOT-22 score of greater than about 7, greater than about 10, greater than about 15, greater than about 20, greater than about 25, greater than about 30, greater than about 35, greater than about 40, greater than about 45, or greater than about 50.
- a "subject in need thereof” may also be a human patient who exhibits a Lund-Mackay score of greater than about 4, greater than about 5, greater than about 6, greater than about 7, greater than about 8, greater than about 9, greater than about 10, greater than about 11, greater than about 12, or greater than about 13.
- a "subject in need thereof” may be a subject who, prior to receiving an IL-4R antagonist, has been prescribed or is currently taking another medication, "a background therapy.”
- the background therapy can be, for example, an intranasal corticosteroid (INCS, or ICS), such as Mometasone furoate nasal spray (MFNS; Nasonex®).
- a "subject in need thereof” is an asthma patient who prior to receiving an IL-4R antagonist, has been prescribed or is currently taking an INCS in combination with a long-acting beta 2 -adronergic antagonist (LABA).
- INCS/LABA therapies include fluticasone/salmeterol combination therapy and budesonide/formoterol combination therapy.
- the background therapy is a nasal saline, a topical decongestant, a topical anesthetic, a leukotriene antagonist or a systemic antihistamine.
- the "subject in need thereof” continues the background therapy after the subject receives the IL-4R antagonist, and in other embodiments, the subject in need thereof stops receiving the background therapy (e.g., at once or gradually) before receiving the IL-4R antagonist.
- Example 1 Clinical Trial of Subcutaneously Administered Anti-IL-4R Antibody (mAb1) In Patients with Persistent Moderate-to-Severe Eosinophilic Asthma, Including Asthma Patients with Chronic Hyperplastic Eosinophilic Sinusitis
- Dupilumab is an anti-IL-4R antibody having a heavy chain variable region of SEQ ID NO:1, and a light chain variable region of SEQ ID NO:2.
- Dupilumab is described in US 7,608,693 .
- the primary objective of the study was to investigate the effects of mAb1 administered subcutaneously once weekly for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbations in patients with persistent moderate-to-severe eosinophilic asthma.
- the secondary objectives of the study were to assess the safety and tolerability of mAb1 administered subcutaneously once weekly for 12 weeks in patients with persistent moderate to severe eosinophilic asthma, and to assess mAb1 serum concentrations following once weekly subcutaneous dosing for 12 weeks in patients with persistent moderate to severe eosinophilic asthma.
- the study comprised a 2-week screening period, a 12-week treatment period comprising a 4-week background therapy stable phase and an 8-week background therapy withdrawal phase post-randomization, followed by an 8-week post-treatment follow-up period.
- the fluticasone dose was reduced by approximately 50%, provided the patient did not meet any of the criteria for an asthma exacerbation (as defined below). If no asthma exacerbations occurred, the ICS withdrawal proceeded according to the following dosing schedule: Background therapy stable phase Background therapy withdrawal phase Week 4 Week 6 Week 7 Week 8 Week 9 Fluticasone/salmeterol (DPI): 250/50 ⁇ g BID Fluticasone (DPI): 250 ⁇ g BID 100 ⁇ g BID 50 ⁇ g BID 0 ⁇ g BID 0 ⁇ g BID Fluticasone/salmeterol (DPI): 500/50 ⁇ g BID Fluticasone (DPI): 500 ⁇ g BID 250 ⁇ g BID 100 ⁇ g BID 50 ⁇ g BID 0 ⁇ g BID Fluticasone/salmeterol (MDI): 230/42 ⁇ g BID Fluticasone (MDI): 220 ⁇ g BID
- FIG. 1 A schematic of the study protocol is provided in Figure 1 .
- Sterile mAb1 150 mg/mL solution for SC injection was provided in a 5 mL glass vial. Each vial contained a withdrawable volume of 2 mL. A 300 mg dose was administered subcutaneously at the study site once weekly in the morning for 12 weeks.
- Placebo Sterile placebo for SC injection was provided in an identically matched 5 mL glass vial. Each vial contained a withdrawable volume of 2 mL. Placebo was administered subcutaneously at the study site once weekly in the morning for 12 weeks.
- any other inhaled steroid other than fluticasone/salmeterol combination therapy or fluticasone administered per the protocol or budesonide/formoterol or mometasone/formoterol during the screening period); systemic or ocular steroids; LABAs other than the salmeterol component of the fluticasone/salmeterol combination therapy administered per the protocol; any other ICS/LABA combination products other than those given above; any inhaled anticholinergic agents (e.g., Ipratropium bromide or tiotropium); methylxanthines (theophylline, aminophyllines); cromones; anti-IgE therapy; lipoxygenase inhibitors; and leukotriene receptor antagonists or leukotriene synthesis inhibitors.
- any other inhaled steroid other than fluticasone/salmeterol combination therapy or fluticasone administered per the protocol (or budesonide/formoterol or momet
- the primary endpoint of this study was the occurrence of an exacerbation of asthma as defined by any of the following: (1) a 30% or greater reduction from baseline in morning peak expiratory flow (PEF) on two consecutive days; or (2) six or more additional reliever puffs of albuterol or levalbuterol in a 24 hour period (compared to baseline) on 2 consecutive days; or (3) deterioration of asthma, as determined by the Investigator, requiring: (a) systemic (oral and/or parenteral) steroid treatment, or (b) an increase in ICS ⁇ 4 times the last dose received prior to discontinuation from the study, or (c) hospitalization.
- PEF morning peak expiratory flow
- Secondary endpoints also included proportion of patients with a composite asthma event defined by a 30% or greater reduction from baseline in morning PEF on two consecutive days together with ⁇ 6 additional reliever puffs of albuterol or levalbuterol in a 24-hour period 9compared to baseline) on 2 consecutive days.
- PEF, ACQ5, asthma symptoms scores, nocturnal awakenings, and reliever medication use were captured in an electronic daily diary. Mean daily nocturnal awakenings, ranging from 0-10, were averaged from the previous 7 days.
- Morning and evening asthma symptom scores consisted of a non-validated patient-reported outcome assessed on a 5-point Likert-type scale, with higher scores indicating worse outcomes (Table 2). Patients recorded overall symptom scores twice a day prior to measuring PEF.
- An Adverse Event is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product.
- An AE can, therefore, be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal (investigational) product.
- AEs also include: any worsening (i.e., any clinically significant change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug; abnormal laboratory findings considered by the Investigator to be clinically significant; and any untoward medical occurrence.
- a Serious Adverse Event is any untoward medical occurrence that at any dose results in death; is life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/ incapacity; is a congenital anomaly/ birth defect; or is an important medical event.
- a logistic regression model was used to compare SAR group with placebo.
- the model included terms for treatment and stratification factor (prior ICS/LABA combination therapy dose).
- the primary analysis was performed based on modified intent-to-treat (mITT) population which included all randomized patients who received at least one dose of mAb1.
- mITT modified intent-to-treat
- a stratified chisquare test was also used to corroborate the primary analysis.
- MMRM mixed-effect model with repeated measures
- the model included change from baseline values up to week 12 as response variables, and factors (fixed effects) for treatment, stratification factor, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction.
- Statistical inferences on treatment comparisons for the change from baseline at week 12 were derived from the mixed-effect model.
- Change from baseline in SNOT-22 was analyzed using an analysis of covariance (ANCOVA), with end of treatment measurements used to impute missing data.
- ANCOVA analysis of covariance
- Pharmacodynamic effects were evaluated using MMRM models in a post hoc fashion. No adjustments were made for multiplicity, since there was only one primary endpoint and analysis.
- Safety variables including AEs, laboratory parameter, vital signs, ECG, clinical laboratory observations and physical examinations were summarized using descriptive statistics.
- ACQ5 denotes the Asthma Control Questionnaire (5 question version), FeNO fraction of exhaled nitric oxide, FEV 1 forced expiratory volume in 1 second, IgE immunoglobulin E, PEF peak expiratory volume, SNOT-22 the 22-item Sinonasal Outcome Test, and TARC thymus and activation regulated chemokine.
- a composite asthma event is defined as a 30% or greater reduction from baseline in morning PEF on 2 consecutive days together with ⁇ 6 additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days.
- Lung function parameters FEV1, AM PEF and PM PEF
- asthma symptom-based endpoints ACQ score, nighttime awakenings
- albuterol use was assessed for each patient at each visit.
- SNOT-22 score was assessed at baseline and at the end of treatment.
- LOCF Week 12
- Table 7 the column labeled "Difference vs. Placebo" reflects the placebo-corrected value from baseline which takes into account changes that are observed in the value of the parameter as compared to the changes that were observed for that parameter in the placebo-treated group. Table 7.
- Placebo 52 0.2 (0.5) 0.1 (0.1) -- mAb1 52 0.4 (0.8) -0.2 (0.1) -0.2 (-0.5, -0.0) 0.0518 SNOT22 Average Score Placebo 51 26.24 (15.62) 0.23 (2.15) ⁇ -- mAb1 50 30.92 (14.77) -8.26 (2.20) ⁇ -8.49 (-13.96, -3.03) 0.0027 ⁇ 51 patients with at least 1 post-baseline assessment. ⁇ 50 patients with at least 1 post-baseline assessment. ⁇ 50 patients with at least 1 post-baseline assessment.
- Treatment with mAb1 resulted in a significant change from baseline in FEV1 at Week 1, which was maintained through Week 12 despite LABA and ICS withdrawal, with a small decrease in FEV1 at Week 5 coinciding with LABA withdrawal. Similar improvements were observed in morning PEF, but less so in evening PEF.
- ACQ5 score improved in both treatment groups at Week 1. However, while ACQ5 improved further with mAb1 between Weeks 1 and 4, the placebo effect stabilized, maintaining the difference through Week 12.
- Morning symptom scores increased from baseline to Week 12 with placebo. With mAb1, there was an initial decrease which remained below baseline through Week 12. A similar pattern (with greater variability) was observed for evening asthma symptom scores.
- Nocturnal awakenings were stable from the placebo group through Week 6, then increased from Weeks 6 to 12. In contrast, nocturnal awakenings decreased in the mAb1 group by Week 1 and remained improved versus baseline through Week 12.
- mAb1 was generally safe and well tolerated.
- Treatment-emergent adverse events were reported similarly by 40 (76.9%) of placebo-treated patients and by 42 (80.8%) of mAb1-treated patients (Table 10).
- TEAEs were non-specific, generally mild to moderate in intensity and the majority recovered by the end of the study.
- SAEs serious adverse events
- the TEAE of angioedema occurred in a 42-year old African-American female after the ninth study treatment dose as a pruritic, popular rash observed at, and distant to, the injection site. It persisted for one week, resolved after study treatment discontinuation, and prednisome and diphenhydramine treatment. It was deemed treatment-related. This AE was subsequent to milder rashes at the injection site after the first and sixth study treatment doses.
- Biomarker analysis was conducted on samples taken from subjects who participated in clinical trials of mAb1 (see Example 1 above).
- serum/plasma biomarkers associated with TH2 inflammation such as thymus and activation chemokine (TARC; CCL17), Immunoglobulin E (IgE), eotaxin-3, periostin, carcinoembryonic antigen (CEA), YKL-40 and blood eosinophils were measured in samples from patients at baseline and at different time points following initiation of study treatment(s). Baseline levels of these biomarkers were assessed for potential predictive value for treatment response.
- fraction of exhaled NO (FeNO) and induced sputum eosinophils and neutrophils were measured as biomarkers of bronchial inflammation.
- Exhaled nitric oxide assessment was conducted prior to spirometry and following a fast of at least 1 hour using a NIOX instrument (Aerocrine AB, Solna, Sweden). Biomarkers were analyzed using a mixed model and the least square mean derived from the model are reported below.
- TARC, eotaxin-3 and IgE remained unchanged in response to placebo.
- TARC levels responded within a week following exposure to mAb1 at 300 mg administered subcutaneously. TARC levels plateau at approximately 50% of the baseline level in mAb1-treated subjects, regardless of ICS withdrawal.
- the data suggest that TARC expression is more directly linked to IL-4R signaling, than FEV1 changes (which drop in parallel to ICS withdrawal [after Week 4]) and that IL-4R blockage induces a shift towards a TH1 signature, as observed with, for example, IFNgamma administration. It might be possible to titrate the mAb1 dose using TARC (and for example CXCL10) in particular in patients requiring long term treatment and at risk for TH1 type immune diseases.
- Total serum IgE also decreased following mAb1 treatment.
- Total serum IgE response was more heterogeneous and delayed compared to TARC response.
- a trend towards IgE decrease in mAb1-exposed patients compared with placebo was observed - however, starting at week 4 only.
- mAb1 treatment was also associated with a significant decrease from baseline in FeNO at Week 4, and FeNo remained below baseline through Week 12, regardless of ICS withdrawal (mean % change at week 12: -28.7 for mAb1 vs 35.0 for placebo; p ⁇ 0.0001).
- placebo FeNo values remained stable through Week 8, followed by an increase at Week 12 coincident with ICS withdrawal.
- Example 2 The positive effect of mAb1 on the SNOT-22 test described in Example 1 suggested that the anti-IL-4R antibody might also be effective for treating nasal polyposis. Further, nasal polyps are most commonly eosinophilic/TH2 driven, and mAb1 significantly reduced biomarkers associated with Th2 inflammation (see Example 2). A clinical trial was therefore designed to test the therapeutic effect of mAb1 on nasal polyposis.
- a randomized, double-blind, phase 2, placebo controlled, 2 arm study will be performed to evaluate mAb1 administered once a week (QW) subcutaneously (SC) for 16 weeks in patients with bilateral nasal polyposis and chronic symptoms of sinusitis.
- the primary objective of the study will be to evaluate the efficacy of mAb1 in the treatment of bilateral nasal polyposis (NP) by assessment of the endoscopic nasal polyp score in comparison to placebo.
- Secondary objectives of the study include evaluation of mAb1 in patients with bilateral nasal polyps with regards to symptoms of sinusitis, Computed Tomography (CT) scan changes, Nasal polyp score in the sub-group of patients with co-morbid asthma, safety and tolerability, pharmacodynamic responses based on suppression of TH2 biomarkers, concentrations of mAb1 in serum, immune response to mAb1 (Anti-drug antibodies (ADA)), and effect of mAb1 in patient reported outcomes and Quality of Life (QoL) scales.
- CT Computed Tomography
- mAb1 will be administered concomitantly with Mometasone furoate nasal spray (MFNS). Also, there is high co-morbidity of NP with asthma, aspirin/ nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity and previous surgeries, and therefore patients will be allowed to enter the study unless they present any of the exclusion criteria described below. Approximately 56 patients will be randomized into 2 treatment groups of 28 patients per group. To ensure at least 28 patients with co-morbid asthma are included in the study, recruitment of NP patients without co-morbid asthma will stop when approximately 28 patients without asthma are randomized. Both the patient and the investigator will be blinded to the assigned treatment group.
- MFNS Mometasone furoate nasal spray
- the study will consist of three periods: 1) a four week screening run in period on MFNS (Visit 1); (2) a 16 week randomized mAb1 or placebo treatment period (Visits 2-18); and (3) a 16 week post-treatment period to assay pharmacokinetics, immunogenicity, safety and efficacy (Visits 19-22).
- the total duration of the study is up to 36 weeks.
- the primary endpoint will be the change from baseline at Week 16 in bilateral nasal polyp score (NPS).
- the 300 mg QW dose regimen is anticipated to saturate apparent target mediated clearance level (10-15 mg/L). This regimen has been tested and provided statistically significant and clinically relevant response in two previous proof of concept studies performed with mAb1 in asthma and atopic dermatitis (see, e.g., Example 1 above, USSN 61/805797 and USSN 61/816191 ).
- the first dose will employ a loading dose of 600 mg in order to achieve faster steady-state concentration. This loading dose range is supported by the acceptable safety profile of the highest loading dose (600 mg) demonstrated in a prior study conducted in Japanese healthy subjects.
- the Cmax after 600 mg loading dose is around 70 mg/L and that the steady state Ctrough of 300 mg QW is around 150 mg/L
- the Cmax after the proposed dosing regimen ie, 600 mg loading dose followed by 300 mg QW
- the mean Cmax of 12 mg/kg IV dose 421 mg/L
- the highest single dose tested in healthy subjects that was well tolerated providing additional confidence that this dose regimen should have an acceptable safety profile.
- Patient inclusion criteria include (i) a physician endoscopic diagnosis of bilateral nasal polyposis (i.e., a minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both nostrils, with at least a score of 2 for each nostril, despite completion of a prior INCS (intranasal corticosteroid) treatment) for at least 8 weeks before screening, and (ii) chronic symptoms of sinusitis, which are the presence of at least two of the following symptoms prior to screening: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; and reduction or loss of smell.
- a physician endoscopic diagnosis of bilateral nasal polyposis i.e., a minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both nostrils, with at least a score of 2 for each nostril, despite completion of a prior INCS (intranasal corticosteroid) treatment) for at least 8 weeks before screening
- chronic symptoms of sinusitis
- Patients with co-morbid asthma are excluded if: the patient has a forced expiratory volume (FEV1) of 60% or less; an exacerbation requiring systemic (oral and/or parenteral) steroid treatment or Hospitalization (>24h) for treatment of asthma, has occurred within 3 months prior screening; or the patient is receiving a dose higher than 1000 ⁇ g fluticasone or the equivalent of inhaled corticosteroids.
- FEV1 forced expiratory volume
- Other exclusion criteria include patients with short life expectancy (less than 6 months); patients receiving concomitant treatment prohibited in the study; women who are pregnant or intend to become pregnant during the study, or breast-feeding women.
- exclusion criteria include concomitant severe diseases (e.g., active and inactive pulmonary tuberculosis, Diabetes mellitus etc.); diagnosed active parasitic infection; suspected or high risk of parasitic infection; history of human immunodeficiency virus (HIV) infection or positive HIV screen at Visit 1; evidence of acute or chronic infection; known or suspected immunosuppression, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), despite infection resolution; live vaccinations within 12 weeks prior to Visit 1 or planned vaccinations during the study; patients with active autoimmune disease or patients using immunosuppressive therapy for autoimmune disease (eg, Hashimoto's thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematous, multiple sclerosis, psoriasis vulgaris
- Sterile mAb1 of various concentrations will be provided in 5 mL glass vials. Each vial will contain a withdrawable volume of 2 mL: 150 mg/mL solution (300 mg dose/ 2 mL). Sterile placebo will be provided in identically matched glass 5 mL vials, where each vial contains a deliverable volume of 2 mL.
- mAb1 will be administered every 7 ⁇ 2 days (QW). The doses of mAb1 will be separated by ⁇ 5 days to avoid an overdose.
- V2 Visit 2
- 2 injections will be performed. After V2 one injection of mAb1 will be performed weekly at the investigational site throughout the randomized treatment period.
- the mAb1 will be administered following clinic procedures and blood collection. Patients will be monitored for at least 1 hour after each administration for any signs or symptoms of a local site injection or hypersensitivity reaction. Subcutaneous injection sites will be alternated between the 4 quadrants of the abdomen (avoiding navel and waist areas) or upper thighs so that the same site is not injected for two consecutive times/weeks.
- Mometasone furoate 50 micrograms/actuation Nasal Spray, is contained in a bottle, that contains 18 g (140 actuations) of product formulation.
- Treatment Period The treatment period will proceed as indicated in the Study Flowchart at Table 14.
- patients will continue the stable dose of mometasone furoate: two actuations of MFNS in each nostril BID or QD (in case patient cannot tolerate the high dose).
- patients will be administered the SNOT-22 test, VAS and QoL questionnaires (SF-36, EQ-5D, Nasal polyp related resource use questionnaire), the smell test, and the ACQ-5 in patients with asthma.
- Clinical laboratory testing at Visit 2 is limited to hematology, pharmacokinetics, anti-drug antibodies, biomarkers in serum and plasma, allergen-specific IgE panel sampling. Blood samples are taken prior to administration of mAb1. Nasal secretion sampling for biomarkers. For those patients who have signed a specific informed consent form, collect blood sample for DNA and RNA sampling (prior to administration of investigational product during the Randomized Treatment Period).
- Temporary treatment discontinuation may be considered by the Investigator because of suspected AEs. Reinitiation of treatment with mAb1 will be done under close and appropriate clinical/and or laboratory monitoring once the Investigator will have considered according to his/her best medical judgment that the responsibility of mAb1 in the occurrence of the concerned event was unlikely and if the selection criteria for the study are still met.
- An adverse event is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
- a serious adverse event is any untoward medical occurrence that at any dose: results in death, or is life-threatening, (the term "life-threatening” in the definition of "serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe); requires inpatient hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect; is a medically important event Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention (ie, specific measures or corrective treatment) to prevent one of the other outcomes listed in the definition above (he following list of medically important events is intended to serve as a guideline for determining which condition has to be considered as a medically important event.
- Post-treatment Period Upon completing the Randomized Treatment Period (or following early discontinuation of mAb1), patients will continue treatment with the stable dose of MFNS maintained over the randomized treatment period, or modify treatment based on medical judgment.
- MFNS MFNS during the screening and throughout the whole study
- Nasal normal saline Nasal normal saline
- Topical decongestants e.g., Oxymetazoline hydrochloride to reduce the swelling and widen the path for the endoscope
- a topical anesthetic e.g. Lidocaine are allowed before endoscopy
- short term use of Antibiotics ⁇ 2weeks
- Methylxanthines e.g., theophylline, aminophyllines.
- inhaled corticosteroids are allowed for patients on a stable dose ⁇ 1000 ⁇ g Fluticasone (or the equivalent dose of another inhaled CS; see Table 16) and only for patients that were on a stable dose ⁇ 30 days prior to Visit 1: Leukotriene antagonists / modifiers are permitted during the study, only for patients that were on a continuous treatment for ⁇ 30 days prior to Visit 1; Systemic antihistamines; and Initiation of allergen immunotherapy (allergen immunotherapy in place for ⁇ 3 months prior to Visit 1 is permitted).
- the primary endpoint of this study is the change from baseline at week 16 in bilateral endoscopic Nasal Polyp Score.
- Table 15 Polyp score Polyp size 0 No polyps 1 Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate 2 Polyps reaching below the lower border of the middle turbinate 3 Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate 4 Large polyps causing complete obstruction of the inferior nasal cavity
- Nasal endoscopy will be performed at the end of the scheduled visits and preceded by local administration of anaesthetic drugs in combination with a decongestant. Standard video sequences will be downloaded or sent to a centralized reader. Centralized imaging data assessments and scoring by an independent physician reviewer for the imaging data will be performed for all endoscopies. To confirm eligibility at V2, only the V1 central reading will be made available to the site. The final results of central reading will be made available after the study.
- central reading of V2 will be used for comparison with EOT reading.
- the sites will remove subject-identifying information from the imaging data header prior to sending the imaging data to the central reader.
- Secondary endpoints of the study will include change from baseline at Week 16 in: patient reported symptoms (including 22-item Sinonasal Outcome Test (SNOT-22)); subject-assessed nasal congestion/obstruction, anterior rhinorrhea (runny nose), posterior rhinorrhea (post nasal drip), and loss of sense of smell, (daily AM and PM e-diary) month average; number of nocturnal awakenings; patient-rated rhinosinusitis symptoms severity using a visual analog scale (VAS); 5-item Asthma control questionnaire (ACQ-5) in asthma sub-group); nasal peak inspiratory flow (NPIF); smell test (UPSIT); NPS in patients with co-morbid asthma; CT scan assessments; Spirometry (overall and in sub-group with asthma); time to first response ( ⁇ 1 point improvement) in NPS; time to study treatment discontinuation; and incidence of treatment discontinuation due to need for OCS or nasal surgery.
- VAS visual analog scale
- ACQ-5 5-item Asthma
- Quality of life (QoL) end points will include change from baseline at Week 16 in: 36-item short form health survey (SF36); European quality of life scale (EQ-5D); and Nasal polyp related resource use questionnaire.
- SF36 36-item short form health survey
- EQ-5D European quality of life scale
- Nasal polyp related resource use questionnaire Nasal polyp related resource use questionnaire
- CT Computed tomography
- EOT Ethymography
- central reading before V2 will be used for comparison with EOT reading.
- the sites will remove subject-identifying information from the imaging data header prior to sending the imaging data to the central reader.
- the % change in opacification from BL to EOT will be calculated.
- AM NPIF morning
- PM evening
- the baseline AM NPIF will be the mean AM measurement recorded for the 28 days prior to the first dose of investigational product
- baseline PM NPIF will be the mean PM measurement recorded for the 28 days prior to the first dose of investigational product.
- Adverse events including serious adverse events (SAEs) and adverse events of special interest (AESI), will be collected at every visit.
- SAEs serious adverse events
- AESI adverse events of special interest
- Predose blood samples will be collected for determination of serum functional mAb1 and anti-mAb1 antibodies as designated in Table 14.
- Functional mAb1 and anti-mAb1 antibodies in serum will be assayed by ELISA.
- Predose functional mAb1 concentrations in serum at Visit 2 (Day 1), mAb1 trough concentrations at Week 2, Week 4, Week 8, Week 12, Week 16, and follow-up serum mAb1 at Week 20, Week 24, Week 28 and Week 32 will be provided.
- Anti-mAb1 antibody status (negative or titer value) at Visit 2 (Day 1), Week 2, Week 4, Week 8, Week 12, Week 16, and Week 32 will also be provided.
- Patients with ADA titers ⁇ 1000 at the end of study visit will be scheduled to return approximately 6 months later for an additional assessment of ADA titer. Further follow-up will be considered based on the overall assessment of antibody titers and clinical presentation.
- biomarkers Since the secretion of certain proteins is dependent, at least in part, on Th2 cytokines and is associated with chronic inflammation of the airway mucosa, including sinus tissue, expression of certain biomarkers will be assayed to monitor a therapeutic effect of mAb1. These biomarkers also will be assessed for their value in predicting toxicity and/or in documenting the time course of drug response. The values to be used as baselines will be those collected on Day 1 (predose assessments).
- Nasal secretions will be obtained by inserting nasal swabs bilaterally into the nasal cavity for five minutes. The nasal secretions will be preserved for possible analysis of additional biomarkers related to nasal polyposis and responses to mAb1 treatment.
- nasal polyp tissue will be optionally obtained by biopsy.
- a baseline biopsy will be obtained at V2 of the study.
- another biopsy of nasal polyp tissue will be obtained at the end of treatment visit (Week 16).
- RNA will be extracted and used for expression profiling (e.g., microarray, transcriptome sequencing or quantitative RT-PCR).
- DNA and RNA samples may be used to determine a possible relationship between genes and response to treatment with mAb1 and possible side effects to mAb1.
- Proportion of patients with binary events will be assessed for : ⁇ 1 point improvement (reduction) in NPS at week 16 (as read centrally); 10% or more improvement in CT opacification from baseline at week 16; drop-out due to oral CS or surgery; or INCS increase after 8 weeks will be analyzed using a logistic model with the above responses, respectively, as the response variable, and treatment group, pooled countries /regions and the stratification factor(s) prior to the study as covariates.
- Time to event e.g., the first response with ⁇ 1 point improvement (reduction) in NPS, study treatment discontinuation, etc
- time to event will be analyzed suing a Cox regression model with time to event as the dependent variable, and treatment, pooled countries/regions, asthma comorbidity prior to the study as covariates.
- the Kaplan-Meier method will be used to derive the proportion of patients with an event at Week 4, 8, 12 and 16 specific to each treatment group. For analysis during the treatment period, if a patient has no event before treatment discontinuation/completion, then the patient will be considered as free of event till the end of treatment period (last dose date + 7 days).
- Subgroup analysis To assess the consistency treatment effects across the subgroup levels and to examine baseline biomarkers for their potential value to predict treatment response, exploratory subgroup analyses will be conducted for the change from baseline in NPS with respect to age group, gender, region, race, INCS dose level, baseline NPS, baseline CT scan score, asthma comorbidity, and selected biomarkers prior to the study.
- ADA titer levels will be classified into categories: Low, moderate and high. Low levels of ADA titers are defined as titers below 1000; moderate levels of ADA titers are defined as titers between 1000 and 10,000; high levels of ADA titers are defined as titers >10,000.
- Anti-mAb1 antibody assay results will be described categorically. The following summary will be provided for: Patients with any positive ADA assay response during the TEAE period; Patients with treatment induced positive ADA assay response during the TEAE period; Patients with treatment induced positive ADA assay response during the TEAE period will be further described as patients with transient positive response and patients with persistent positive response. Patients with any positive ADA assay response during the TEAE period is defined as those having at least one sample positive in the ADA assay.
- the treatment induced positive ADA assay response is defined as: Patients with no positive assay response at baseline but with a positive assay response during the TEAE period or patients with a positive ADA assay response at baseline and also have at least a 4-fold increase in titer during the TEAE period.
- a persistent positive response is a treatment induced positive ADA assay response in which at least 2 consecutive post-baseline samples from a patient are positive in the ADA assay or the last post-baseline sample collected is positive in the ADA assay.
- a transient positive response is defined as any treatment induced positive ADA assay response that is not considered persistent. Table 16. Allowable Inhaled Glucocorticosteroid / Long-Acting Beta2 Agonist Combination Products and Acceptable Dosage Form.
- the invention pertains also to the following:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837912P | 2013-06-21 | 2013-06-21 | |
EP14305670 | 2014-05-07 | ||
PCT/US2014/043440 WO2014205365A1 (fr) | 2013-06-21 | 2014-06-20 | Méthodes de traitement de la polypose nasale par administration d'un antagoniste d'il-4 r |
EP14742021.0A EP3010539B1 (fr) | 2013-06-21 | 2014-06-20 | Méthodes de traitement de la polypose nasale par administration d'un antagoniste d'il-4 r |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14742021.0A Division EP3010539B1 (fr) | 2013-06-21 | 2014-06-20 | Méthodes de traitement de la polypose nasale par administration d'un antagoniste d'il-4 r |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3613432A1 true EP3613432A1 (fr) | 2020-02-26 |
Family
ID=50736018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19187112.8A Pending EP3613432A1 (fr) | 2013-06-21 | 2014-06-20 | Procédés de traitement de la polypose nasale par administration d'un antagoniste il-4r |
EP14742021.0A Active EP3010539B1 (fr) | 2013-06-21 | 2014-06-20 | Méthodes de traitement de la polypose nasale par administration d'un antagoniste d'il-4 r |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14742021.0A Active EP3010539B1 (fr) | 2013-06-21 | 2014-06-20 | Méthodes de traitement de la polypose nasale par administration d'un antagoniste d'il-4 r |
Country Status (18)
Country | Link |
---|---|
US (2) | US10059771B2 (fr) |
EP (2) | EP3613432A1 (fr) |
JP (1) | JP6463351B2 (fr) |
KR (3) | KR20230066127A (fr) |
CN (2) | CN105517570B (fr) |
AU (3) | AU2014284235B2 (fr) |
CA (1) | CA2915839A1 (fr) |
CY (1) | CY1122754T1 (fr) |
HK (1) | HK1222567A1 (fr) |
IL (1) | IL243246B (fr) |
MX (1) | MX368068B (fr) |
PL (1) | PL3010539T3 (fr) |
RS (1) | RS59354B1 (fr) |
RU (1) | RU2674680C2 (fr) |
SG (2) | SG10201710557QA (fr) |
SI (1) | SI3010539T1 (fr) |
TW (2) | TWI757893B (fr) |
WO (1) | WO2014205365A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
US11214621B2 (en) | 2014-11-14 | 2022-01-04 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
US11845800B2 (en) | 2012-08-21 | 2023-12-19 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
KR20230066127A (ko) | 2013-06-21 | 2023-05-12 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법 |
SG10201912898XA (en) * | 2013-06-21 | 2020-02-27 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by adding an IL-4R antagonist |
AU2015222951B2 (en) | 2014-02-28 | 2020-06-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an IL-4R antagonist |
PL3416685T3 (pl) * | 2016-02-19 | 2024-08-26 | Regeneron Pharmaceuticals, Inc. | Sposoby wzmocnienia skuteczności szczepionki przez podawanie antagonisty il-4r |
MA46098A (fr) * | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
WO2018057776A1 (fr) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r |
TWI784988B (zh) * | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
CN108339118A (zh) * | 2017-01-23 | 2018-07-31 | 瑞阳(苏州)生物科技有限公司 | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 |
WO2019028367A1 (fr) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles active |
GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
KR20210010518A (ko) | 2018-05-13 | 2021-01-27 | 리제너론 파아마슈티컬스, 인크. | Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법 |
US20210403580A1 (en) * | 2018-11-09 | 2021-12-30 | Ajou University Industry-Academic Cooperation Foundation | Human antibody having high affinity to human il-4 receptor alpha, and use thereof |
CN111494625B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
KR20210136071A (ko) * | 2019-03-06 | 2021-11-16 | 리제너론 파아마슈티컬스, 인크. | 암을 치료하는데 있어서 증진된 효능을 위한 il-4/il-13 경로 억제제 |
JP2022526738A (ja) | 2019-03-21 | 2022-05-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アレルギーを治療するためのil-4/il-13経路阻害剤と形質細胞除去の組み合わせ |
KR20220044563A (ko) | 2019-08-05 | 2022-04-08 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법 |
US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
BR112022003464A2 (pt) | 2019-09-20 | 2022-05-24 | Maruho Kk | Composição farmacêutica |
CA3161037A1 (fr) | 2019-12-09 | 2021-06-17 | Sanofi Biotechnology | Methodesde traitement de troubles associes a l'il-4/il-13 identifies numeriquement |
EP3992974A1 (fr) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Procédés pour le traitement de troubles liés à l'il-13/il-4 identifiés numériquement |
CN117693362A (zh) * | 2021-08-02 | 2024-03-12 | 甘李药业股份有限公司 | 含有抗il-4r抗体的稳定制剂 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US7186809B2 (en) | 2000-05-26 | 2007-03-06 | Immunex Corporation | Methods and compositions relating to anti-interleukin-4 receptor antibodies |
US7582298B2 (en) | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
US7605237B2 (en) | 2006-10-02 | 2009-10-20 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
WO2010120524A2 (fr) * | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Procédés de modulation d'une réponse immunitaire à une infection virale |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
WO2012047954A1 (fr) * | 2010-10-06 | 2012-04-12 | Regeneron Pharmaceuticals, Inc. | Formulations stabilisées contenant des anticorps anti-récepteur de l'interleukine-4 (il-4r) |
US20120240930A1 (en) * | 2010-03-16 | 2012-09-27 | Dan Allan Robert Kristensson | Treatment of Asthma, Allergic Rhinitis and Improvement of Quality of Sleep by Temperature Controlled Laminar Airflow Treatment |
US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
WO2015127229A1 (fr) * | 2014-02-21 | 2015-08-27 | Sanofi | Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-4 r |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (fr) | 1992-12-29 | 1994-07-06 | Schering-Plough | Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
DE60130466T2 (de) | 2000-07-26 | 2008-06-12 | Hououdou Co. Ltd. | Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
US7208579B2 (en) * | 2003-05-30 | 2007-04-24 | The Regents Of The University Of California | IL4 receptor antagonists for horse, dog and cat |
GEP20104991B (en) | 2003-11-07 | 2010-05-25 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
WO2005063817A2 (fr) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Procédés d'identification d'anticorps fonctionnels |
JP2008504806A (ja) | 2004-02-27 | 2008-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il−4/il−13特異的ポリペプチドおよびその治療上の使用 |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
EP2022507A1 (fr) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Compositions d'anticorps spécifiques pour les épitopes des lgE, lgG4 et lgA en tant qu'outils pour la création de molécules hypoallergéniques pour l'immunothérapie spécifique |
EP2245064B1 (fr) * | 2007-12-21 | 2014-07-23 | Medimmune Limited | ELEMENTS DE LIAISON POUR LE RECEPTEUR ALPHA DE L'INTERLEUKINE-4 (IL-4Ralpha) |
US20110008326A1 (en) * | 2008-04-02 | 2011-01-13 | Oliver Hill | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
AU2009322556A1 (en) | 2008-12-01 | 2011-07-21 | Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
RU2403071C1 (ru) * | 2009-09-03 | 2010-11-10 | Логина Наталия Алексеевна | Способ лечения хронических рецидивирующих воспалительных заболеваний слизистой носа и околоносовых пазух методом эндоназальной аутолимфоцитотерапии |
UA111731C2 (uk) * | 2010-10-06 | 2016-06-10 | Рідженерон Фармасьютікалз, Інк. | Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти |
RU2469737C1 (ru) * | 2011-06-28 | 2012-12-20 | Федеральное государственное учреждение "Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи" Министерства здравоохранения и социального развития России (СПб НИИ ЛОР МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) | Способ лечения хронического риносинусита |
SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
CN110624107A (zh) | 2012-08-21 | 2019-12-31 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
RS57520B1 (sr) | 2012-09-07 | 2018-10-31 | Regeneron Pharma | Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r |
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
KR20230066127A (ko) | 2013-06-21 | 2023-05-12 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법 |
MX2017006286A (es) | 2014-11-14 | 2018-01-23 | Sanofi Biotechnology | Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r. |
-
2014
- 2014-06-20 KR KR1020237014744A patent/KR20230066127A/ko not_active Application Discontinuation
- 2014-06-20 KR KR1020217034479A patent/KR20210132232A/ko not_active IP Right Cessation
- 2014-06-20 CN CN201480035350.XA patent/CN105517570B/zh active Active
- 2014-06-20 SI SI201431352T patent/SI3010539T1/sl unknown
- 2014-06-20 SG SG10201710557QA patent/SG10201710557QA/en unknown
- 2014-06-20 TW TW109133577A patent/TWI757893B/zh active
- 2014-06-20 RU RU2016101632A patent/RU2674680C2/ru active
- 2014-06-20 PL PL14742021T patent/PL3010539T3/pl unknown
- 2014-06-20 TW TW103121405A patent/TWI709411B/zh active
- 2014-06-20 SG SG11201509625PA patent/SG11201509625PA/en unknown
- 2014-06-20 EP EP19187112.8A patent/EP3613432A1/fr active Pending
- 2014-06-20 RS RSP20191274 patent/RS59354B1/sr unknown
- 2014-06-20 EP EP14742021.0A patent/EP3010539B1/fr active Active
- 2014-06-20 AU AU2014284235A patent/AU2014284235B2/en active Active
- 2014-06-20 JP JP2016521853A patent/JP6463351B2/ja active Active
- 2014-06-20 KR KR1020167000981A patent/KR20160024916A/ko active Application Filing
- 2014-06-20 MX MX2015017970A patent/MX368068B/es active IP Right Grant
- 2014-06-20 CN CN202010182762.3A patent/CN111437387B/zh active Active
- 2014-06-20 US US14/310,419 patent/US10059771B2/en active Active
- 2014-06-20 WO PCT/US2014/043440 patent/WO2014205365A1/fr active Application Filing
- 2014-06-20 CA CA2915839A patent/CA2915839A1/fr active Pending
-
2015
- 2015-12-20 IL IL243246A patent/IL243246B/en active IP Right Grant
-
2016
- 2016-09-13 HK HK16110805.6A patent/HK1222567A1/zh unknown
-
2018
- 2018-07-18 US US16/038,816 patent/US20190040146A1/en active Pending
-
2019
- 2019-10-24 CY CY20191101111T patent/CY1122754T1/el unknown
- 2019-11-07 AU AU2019261751A patent/AU2019261751B2/en active Active
-
2022
- 2022-02-25 AU AU2022201336A patent/AU2022201336A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US7186809B2 (en) | 2000-05-26 | 2007-03-06 | Immunex Corporation | Methods and compositions relating to anti-interleukin-4 receptor antibodies |
US7582298B2 (en) | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
US7605237B2 (en) | 2006-10-02 | 2009-10-20 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
WO2010120524A2 (fr) * | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Procédés de modulation d'une réponse immunitaire à une infection virale |
US20120240930A1 (en) * | 2010-03-16 | 2012-09-27 | Dan Allan Robert Kristensson | Treatment of Asthma, Allergic Rhinitis and Improvement of Quality of Sleep by Temperature Controlled Laminar Airflow Treatment |
WO2012047954A1 (fr) * | 2010-10-06 | 2012-04-12 | Regeneron Pharmaceuticals, Inc. | Formulations stabilisées contenant des anticorps anti-récepteur de l'interleukine-4 (il-4r) |
US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
WO2015127229A1 (fr) * | 2014-02-21 | 2015-08-27 | Sanofi | Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-4 r |
Non-Patent Citations (20)
Title |
---|
"Medical Applications of Controlled Release", 1974, CRC PRES. |
ANGAL ET AL., MOLECULAR IMMUNOLOGY, vol. 30, 1993, pages 105 |
BACHERT C ET AL: "Pharmacological management of nasal polyposis", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 65, no. 11, 1 January 2005 (2005-01-01), pages 1537 - 1552, XP002697885, ISSN: 0012-6667 * |
C. HOPKINS ET AL: "Psychometric validity of the 22-item Sinonasal Outcome Test", CLINICAL OTOLARYNGOLOGY, vol. 34, no. 5, 1 October 2009 (2009-10-01), pages 447 - 454, XP055141534, ISSN: 1749-4478, DOI: 10.1111/j.1749-4486.2009.01995.x * |
CORREN ET AL., AM J RESPIR CRIT CARE MED., vol. 181, no. 8, 2010, pages 788 - 796 |
D. LEZCANO-MEZA ET AL: "Interleukin (IL)-4 and to a lesser extent either IL-13 or interferon-gamma regulate the production of eotaxin-2/CCL24 in nasal polyps", ALLERGY, vol. 58, no. 10, 1 October 2003 (2003-10-01), pages 1011 - 1017, XP055141429, ISSN: 0105-4538, DOI: 10.1034/j.1398-9995.2003.00174.x * |
GEVAERT ET AL: "Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 118, no. 5, 6 November 2006 (2006-11-06), pages 1133 - 1141, XP005844189, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2006.05.031 * |
GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138 |
HOPKINS ET AL., CLIN. OTOLARYNGOL., vol. 34, 2009, pages 447 - 454 |
HOPKINS ET AL: "The Lund-Mackay staging system for chronic rhinosinusitis: How is it used and what does it predict?", OTOLARYNGOLOGY AND HEAD AND NECK SURGERY, ROCHESTER, US, vol. 137, no. 4, 25 September 2007 (2007-09-25), pages 555 - 561, XP022266576, ISSN: 0194-5998, DOI: 10.1016/J.OTOHNS.2007.02.004 * |
KLEMENTINA AVDEEVA ET AL: "Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps", CURRENT ALLERGY AND ASTHMA REPORTS, vol. 18, no. 4, 24 March 2018 (2018-03-24), US, XP055531490, ISSN: 1529-7322, DOI: 10.1007/s11882-018-0776-8 * |
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533 |
MORDENTI ET AL., PHARMACEUT. RES., vol. 8, 1991, pages 1351 |
N. A. MOLFINO ET AL: "Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor", CLINICAL & EXPERIMENTAL ALLERGY, vol. 42, no. 5, 1 May 2012 (2012-05-01), pages 712 - 737, XP055026155, ISSN: 0954-7894, DOI: 10.1111/j.1365-2222.2011.03854.x * |
NACLERIO ROBERT M ET AL: "Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 139, no. 2, 1 February 2017 (2017-02-01), XP029936317, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2016.12.245 * |
POWELL ET AL.: "Compendium of excipients for parenteral formulations", J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311, XP009119027 |
SCAVUZZO M C ET AL: "Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, FR, vol. 59, no. 6, 1 July 2005 (2005-07-01), pages 323 - 329, XP027640155, ISSN: 0753-3322, [retrieved on 20050701] * |
SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 201 |
TAYLOR ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295 |
WU ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11845800B2 (en) | 2012-08-21 | 2023-12-19 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
US11214621B2 (en) | 2014-11-14 | 2022-01-04 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019261751B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
US20220204631A1 (en) | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist | |
EP4011915A1 (fr) | Procédés de traitement ou de prévention de l'asthme par administration d'un antagoniste il-4r | |
JP7216122B2 (ja) | Il-4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法 | |
JP6898421B2 (ja) | Il−4rアンタゴニストの投与により鼻茸を処置する方法 | |
NZ752224B2 (en) | Methods for treating nasal polyposis by administering an il-4r antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3010539 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200826 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40023224 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240215 |